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Abstract 
 It was recently shown that inhibition or downregulation of Bcl-2 represents a 
new therapeutic approach to by-pass chemoresistance mechanism in cancer cells. 
Therefore, we explored the potential of this approach in breast cancer cells; MCF-7 
(drug-sensitive; p53 wild type) and MDA-MB-231 (drug-insensitive; p53 mutant). 
Cisplatin and paclitaxel induced apoptosis in a dose-dependent manner in both cell 
lines. Furthermore, silencing of Bcl-2 remarkably increased cisplatin and paclitaxel 
induced apoptosis. Dose dependent induction of apoptosis by cisplatin and paclitaxel 
was enhanced by the pre-treatment of these cells with HA14-1, a Bcl-2 inhibitor. 
Although the effect of cisplatin on cell death was significant in MCF-7 and MDA-MB-
231, paclitaxel was less potent only in MDA-MB-231 cells. 
 To further understand the distinct role of drugs in breast cancer cells which were 
pre-treated with HA14-1, changes in mitochondrial membrane potential, caspase 
activation, and Bcl-2 family protein levels, generation of reactive oxygen species and 
lipid peroxidation were studied. The apoptotic effect of cisplatin with or without HA14-
1 pre-treatment was shown to be caspase-dependent in both cell lines. While pro-
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apoptotic Bcl-2 proteins (Bax, Puma, Bad) were found to be up-regulated, Bcl-2 and 
Bcl-xL were down-regulated when cells were pre-treated with HA14-1 followed by 
cisplatin or paclitaxel. MCF-7 and MDA-MB-231 cells overexpressing Bcl-2 displayed 
different responses upon drug-treatment. Although cisplatin could still induce apoptosis 
in Bcl-2 overexpressing MCF-7 cells by promoting pro-apoptotic Bcl-2 family 
members, Bcl-2 overexpression abrogated paclitaxel induced apoptosis in MCF-7 and 
MDA-MB-231 breast cancer cells, respectively. 
 In conclusion, our findings suggest two important implications for understanding 
cisplatin and paclitaxel induced apoptosis mechanism and the potential role of Bcl-2 in 
this apoptotic pathway. First, the potentiating effect of Bcl-2 inhibitor (HA14-1) is drug 
and cell type specific and may not only depend on the inhibition of Bcl-2. Importantly, 
alteration of other pro-apoptotic or anti-apoptotic Bcl-2 family members may dictate the 
apoptotic response when HA14-1 is combined with chemotherapeutic drugs. Second, 
cisplatin activated a p53- regulated pro-apoptotic pathway to overcome Bcl-2 mediated 
resistance. These insights may be useful for the development of novel treatments for 
cancer cells overexpressing anti-apoptotic Bcl-2 proteins. 
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ÖSTROJEN RESEPTÖR alfa +/- MCF-7 ve MDA-MB-231 MEME 
KANSERİ HÜCRELERİNDE İLAÇLARCA TETİKLENEN APOPTOZ 
VE İLACA DİRENÇ MOLEKÜLER MEKANİZMASI 
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Özet 
 
Çok yakın bir zamanda Bcl-2’nin aktivitesinin azalması veya protein anlatımının 
azaltılması yeni bir terapotik yaklaşım olarak gösterilmiş ve böylece kanser hücreleri 
tarafından ilaçlara gösterilen cevapsızlık mekanizmasının aşılabileceği ortaya 
konulmuştur. Bu nedenle, bu yaklaşımın potansiyel etkileri meme kanseri hücrelerinde 
(MCF-7, p53 doğal tip ve ilaca duyarlı; MDA-MB-231 p53 mutant, ilaca duyarsız) 
araştırılmıştır. Sisplatin ve paklitaksel hücrelerde farklı şekillerde ölümü tetikleyen 
kemoterapötik ajanlar olup, MCF-7 ve MDA-MB-231 hücrelerinde sırası ile doza bağlı 
sitotoksik ve apoptotik etkiler göstermişlerdir. Buna ilaveten, her iki hücre hattında da 
geçici Bcl-2 siRNA uygulamasının ardından sisplatin ve paklitaksel uygulandığında, 
Bcl-2 siRNA uygulaması yapılmamış kontrol hücrelere göre, sisplatin ve paklitaksel 
daha fazla apoptotik etkiye neden olmuştur. MCF-7 ve MDA-MB-231 hücrelerine Bcl-2 
inhibitörü, HA14-1 ön uygulamasını takiben değişik dozlarda ilaç uygulaması 
yapılmıştır. HA14-1 ön uygulamasının sisplatin ve paklitaksel tarafından tetiklenen 
apoptotik etkiyi arttırdığı tespit edilmiştir. Ancak bu etki MCF-7 meme kanseri 
hücrelerinde her iki ilaç için daha anlamlı bulunurken, HA14-1 ön uygulamasının 
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ardından paklitaksel uygulaması yapılan MDA-MB-231 hücrelerinde daha az etki tespit 
edilmiştir. 
İlaçlar tarafından tetiklenen apoptoz mekanizmasındaki farklılıkları anlamak 
üzere hücrelerde mitokondri zar potansiyelindeki azalmada görülen değişimler, kaspaz 
aktivitesi, Bcl-2 ailesinin anlatımlarındaki değişiklikler, reaktif oksijen türlerinin ve 
lipid peroksidasyonu hücrelere sisplatin ve paklitaksel uygulaması sonrasında 
belirlenmiştir. Sisplatin Bcl-2 inhibitörü varlığında veya tek başına uygulandığı zaman 
kaspaz aktivitesine bağlı olarak apoptotik yolağı tetiklediği gösterilmiştir. 
Kemoterapötik ilaçların meme kanseri hücrelerinde pro-apoptotik proteinlerin 
anlatımlarını arttırırken (Bax, Puma, Bad), anti-apoptotik proteinlerin (Bcl-2 ve Bcl-xL) 
anlatımlarının ise kontrol hücrelere oranla azaldığı tespit edilmiştir. Bcl-2 anlatımı 
arttırılmış MCF-7 ve MDA-MB-231 hücrelerinde sisplatin apoptozu 48 saat içinde 
tetiklerken, paclitaksel ve HA14-1 bu etkiyi göstermemişlerdir. Bcl-2 anlatımı 
fazlalaştırılmış MDA-MB-231 hücrelerinin ise MCF-7 hücrelerine gore sisplatine daha 
dirençli oldukları saptanmıştır.  
Sonuç olarak, bulgularımız sisplatin ve paklitaksel tarafından tetiklenen apoptoz 
mekanizması ve apoptotik yolakta Bcl-2 in rolü üzerine iki önemli çıkarımı 
önermektedir: Birincisi, Bcl-2 inhibitörünün (HA14-1) olası etkisi ilaç ve hücre tipine 
özgüdür ve sadece Bcl-2 inhibisyonuna bağlı etki göstermeyebilir. En önemlisi, Bcl-2 
inhibitörü ile kombine edilen ilaçlarca tetiklenen apoptoz mekanizmasında diğer Bcl-2 
ailesi üyelerinde görülen değişimlerin belirleyici olabileceğidir. İkinci durum ise, 
sisplatin p53 tarafından düzenlenen bir pro-apoptotik yolağı aktive etmekte ve Bcl-2 
tarafından oluşturulmuş direnci aşabilmektedir. Bu bilgiler Bcl-2 anti-apoptotik 
proteinlerinin aşırı anlatımı görülen kanser hücrelerinde yeni uygulama tiplerinin 
gelişmesinde yararlı olabilir. 
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1 INTRODUCTION 
Cancer formation or malignant cell turnover requires the acquisition of six 
fundamental properties: self-sufficient proliferation, insensitivity to anti-proliferative 
signals, evasion of apoptosis, unlimited replicative potential, the maintenance of 
vascularization, and, for malignancy, tissue invasion and metastasis. Therefore cancer is 
a really complex problem and solutions seem to like fuzzy logic. In fact, fuzzy logic 
approach reveals that cells have inner workers which cross talks with each other. This is 
also referred as signaling network which has its own set of rules that determine how it 
responds to a particular stimulus. Despite the many hundreds of molecules involved in 
carcinogenesis, there are several families of star players in the story of carcinogenesis.  
One of the goals of cancer research is to develop new effective and non-toxic 
cancer therapies. It is shown that the ability to trigger death in tumor cells is an 
important strategic design for cancer therapeutics. This is supported by the fact that 
many successful conventional therapies work by triggering apoptosis albeit indirectly. 
Molecular oncology mainly can be defined as using knowledge of the molecular players 
in the cell death pathway which enable us to design direct and the most appropriate 
apoptotic inducers. According to histopathological and clinical observations, it is 
obvious that more complex therapy tools and monitoring substances at molecular level 
with better understanding of their network signaling mechanisms are required. 
However, chemoresistance mechanism is the major obstacle in cancer therapy. 
Generally, classical chemotherapeutics are extracted from natural sources or designed 
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specially to target a specific place. Although presence of new scientific tools, typical 
drug discovery process takes 10 to 15 years which has high costs varies from US$ 897 
million to US$ 1.9 billion. To develop smart drugs, a series of stages should be 
followed by application of multi-disciplinary knowledge. Thus, instead of cancer 
researchers, Bioinformatians, computer science workers, pure physicist and chemistry 
researchers, pharmaceutical academics and manufacturers, different kinds of 
engineering branches may carry out the different stages at different facilities.  
Since Bcl-2 is overexpressed in a broad range of tumors, inhibition of its 
expression by any tool provide a therapeutic strategies. Furthermore, over-expression 
anti-apoptotic Bcl-2 proteins has been associated chemotherapy resistance. Therefore 
Bcl-2 family can be referred as a star player and targetting each member is an important 
target for the design of apoptotic drugs. Three main strategies have been used to 
modulate their expression: a. antisense RNA or oligonucleotides, b. small molecules to 
inhibit protein function and protein-protein interactions of anti-apoptotic molecules, 
drugs, c. drugs that induce the activity of pro-apoptotic molecules. Following death 
stimuli, these proteins are modulated and death decision is finalized. 
In this study, our aim was to characterize the possible role of Bcl-2 in drug-
induced apoptosis mechanism. Here, we demonstrated that transiently silencing of Bcl-2 
increased the apoptotic effect of cisplatin and paclitaxel in both cell lines. Chemical 
inhibition of Bcl-2 by specific small molecule, HA14-1 enhanced the cisplatin and 
paclitaxel apoptosis in MCF-7 cells. Pre-treatment of HA14-1 significantly enhanced 
the cisplatin induced apoptosis in MDA-MB-231 cells, but paclitaxel was found to be 
much less potent. This selective sensitizing effect of HA14-1 was shown to be via 
modulation of other pro or anti-apoptotic Bcl-2 family members. Cisplatin activates a 
pro-apoptotic pathway that bypasses Bcl-2 mediated protection against apoptosis in Bcl-
2 over-expressing MCF-7 cells. However, cisplatin did not induce apoptosis in Bcl-2 
over-expressing MDA-MB-231 cells. Interestingly, paclitaxel treatment did not lead to 
apoptosis in Bcl-2 over-expressing MCF-7 cells. Lastly reactive oxygen species (ROS) 
generation and lipid peroxide levels were determined in MCF-7 and MDA-MB-231 
cells to assess anti-antioxidant role of Bcl-2 in drug-induced apoptosis mechanism. 
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A chapter for the background follows introduction section which explains current 
studies and baseline information about our hypothesis. This chapter is followed by 
Chapter 3, which explains material and methods utilized in this study in a detailed 
fashion. The results are presented in Chapter 4. Discussion part is placed in Chapter 5 in 
the light of current and past literature. Finally, Chapter 6 gives brief synopsis and 
conclusions of this study along with future perspectives. 
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CHAPTER 2 
 
 
 
 
 
 
2 BACKROUND 
2.1 Cancer 
Cancer can be simply characterized by uncontrolled cell growth and spread of 
abnormal cells. Generally two basic reasons trigger the malignant cell transformation. 
One of them is external factors such as smoking, diet, life style, chemicals, infections, 
pollution or radiation. Intrinsic factors such as hereditary factors, deleterious mutations, 
immune system capability, hormones are also important determinatives in malign cell 
transformation. Therefore eliminating some external factors such as smoking, low 
carbohydrate diet or doing regular exercise might be important in prevention of cancer 
during lifespan. Although cancer is a multi-step disease and one of these factors can be 
enough to promote disease.  
A confluence of discoveries in the mid- and late nineteenth century led to our 
understanding of how tissues and complex organisms arise from fertilized eggs. The 
most fundamental of these was the discovery that all tissues are composed of cells and 
cell products, and that all cells arise through the division of pre-existing cells. That 
means the egg is the source of all cell lineages. Therefore in principle, each cell carries 
some clues about its origin. According to histopathological investigations of tumor 
sections it is possible that the source of tumor cells can be traced back and origin of the 
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malign formation can be identified. Moreover, pathological and biochemical approaches 
provide detailed understanding of clinical behavior of tumor. Tumors are segregated 
into two broad classes depending on their degree of aggressive growth. Those that grew 
locally without invading adjacent tissues were classified as benign. Other that invaded 
nearby tissues and spawned metastases were termed malignant [1]. 
These malfunctioning cells are starting point of disorganized tissue architecture of 
tumors. Tumors are classified into four groups according to their origin (epithelial, 
mesenchymal, hematopoetic and neuroectodermal). Virtually all cell types in the body 
can give rise to cancer, but the most common human cancers are of epithelial origin-
carcinomas. A number of carcinomas separated into two categories: squamous cell 
carcinomas which arise from epithelia, while adenocarcinomas arise from secretory 
epithelia. Non-epithelial malignant tumors include sarcomas which originate from 
mesenchymal cells, hematopoietic cancers, which arise from cells of the circulatory and 
the immune systems and neuroectodermal tumors, which originate from components of 
the nervous system. However some tumors which are said to be anaplastic do not fit this 
classification scheme [1] 
Although the incidence of some cancers is comparable worldwide, many of them 
vary dramatically by country and therefore cannot be due simply to a normal biological 
process gonee awry by chance. Differences in heredity or environmental might well 
explain these differences; in fact, epidemiologic studies have shown that environment is 
the dominant determinant of the country-based variations in cancer incidence [1]. 
Cancer is the second leading cause of death after cardiovascular diseases in 
economically developed countries and causes one of eight deaths worldwide. This ratio 
is greater than AIDS, tuberculosis and malaria. In developing countries, cancer is third 
cause of death after cardiovascular and gastrointestinal infections. In 2007, more than 
12 million new cancer cases were estimated worldwide, of which 5.4 million in 
economical developed countries and 6.7 million in developing countries. Again in 2007, 
it was estimated 20000 deaths per day. By 2050, the global burden is expected to grow 
to 27 million new cancer cases and 17.5 million cancer deaths simply due to the growth 
and aging of the population (Figure 2.1) [1]. 
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Figure 2.1 Leading sites of new cancer cases and deaths worldwide by level of 
economic development, 2007. Estimates were produced by applying age-specific 
cancer rates of a defined geographic region (worldwide, developed and 
developing countries) from GLOBOCAN 2002 to the corresponding age-specific 
population for the year 2007 from the United Nations population projections 
(2004 version). Therefore, estimates for developed and developing countries 
combined do not sum to worldwide estimates. *Excludes non-melanoma skin 
cancer. Adopted from [1]. 
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In economically developed countries, the three most commonly diagnosed cancers 
are prostate, lung and bronchus, and colorectal among men and breast, colorectal, and 
lung and bronchus among women. Whereas, in economically developing countries, the 
three most commonly diagnosed cancers are lung and bronchus, stomach, and liver in 
men, and breast, cervix uteri, and stomach in women. In both economically developed 
and developing countries, the three most common cancer sites are also the three leading 
causes of death. This statistical data verifies that why lung, bronchus, breast and 
colorectal cancers are the most common cancer types due to Western style eating habits 
with high carbohydrate and lipid uptake and smoking [1]. 
2.1.1 Breast cancer 
Breast cancer represents the most common cancer and the second cause of cancer 
death in women in the Western world [2]. According to National Cancer Institute 
statistical prediction, approximately 1.5 million new cases and a half million mortality 
rates were expecting in women as a result of breast cancer (Figure 2.1). Moreover, The 
National Cancer Institute estimates that approximately 2.4 million women with a history 
of breast cancer were alive in January, 2004. Most of them were cancer free [1]. 
Although mortality rates have recently been decreasing because of earlier diagnosis and 
adjuvant therapies, once metastases develop the disease is incurable. Metastatic breast 
cancer has a median survival of just 15 to 20 months. Cytotoxic chemotherapy is 
generally the treatment of choice for women with hormone insensitive, extensive 
visceral or rapidly progressive disease [3]. 
This disease is controlled by surgery and radiotherapy, and is commonly 
supported by adjuvant chemotherapies or hormonotherapies [4]. It is well established 
that the ovarian hormones, estrogen and progesterone, are essential for the growth and 
maintenance of the mammary ductal tissue [5]. During postlactational regression of 
breasts, extensive apoptosis of ductal cells is required, whereas myoepithelial cells and 
basal lamina persist, and are reused during the resumption of extensive cell 
proliferation. Breast tumor cells are also heavily dependent on estrogen and 
progesterone hormones for their maintenance and growth [6]. Fortunately, very effective 
antagonists for these hormones exist, such as tamoxifen, which is widely used for the 
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treatment of these tumor types usually subsequent to surgical resection [7]. However, 
occasional loss of receptors due to genetic lesions in tumor cells and overexpression of 
drug efflux pumps lead to resistance towards hormone-mimetic drugs as well as other 
chemotherapeutic agents. Although second-generation selective estrogen receptor 
modulators such as raloxifene and second-line treatment options such as the aromatase 
inhibitors (letrozole and anastrazole) are somewhat effective, they are primarily useful 
against tumors that have a positive hormone receptor status. The challenge, thus, lies in 
the emergence of hormone-refractory tumors which no longer respond to the anti-
hormone therapy. 
2.1.2 Chemotherapeutics 
2.1.2.1 Cisplatin 
The treatment of anti-estrogens for estrogen-responsive breast cancers has been 
used for almost three decades. However, a major problem with the use of anti-estrogens 
is that most patients with advanced breast cancer eventually develop resistance to the 
compounds. Several mechanisms have been proposed to understand the molecular basis 
of resistance, including loss of estrogen receptor-  (ERα) expression, posttranslational 
modifications of the estrogen receptor, and changes in signal transduction [8].  
Cisplatin (cis-diamminedichloroplatinum II) is a platinum compound used for 
treatment of a variety of cancers. It was reported that cisplatin is active in breast 
carcinoma given alone or in combination with other chemotherapeutic drugs. In women 
with human epidermal growth factor-2 (HER2)-positive metastatic breast cancer, 
treatment with cisplatin, or the related carboplatin, in combination with taxanes and 
trastuzumab (Herceptin) shows promising results. Cisplatin induces intrastrand and 
interstrand cross-links in DNA, resulting in DNA adducts, which is followed by 
induction of cell death [9]. Once cisplatin enters a cell its chloride ligands are replaced 
by water molecules generating a positively charged aquated species that can react with 
nucleophilic sites on intracellular macromolecules to form protein, RNA and DNA 
adducts [10]. Cisplatin activates caspases through different signaling pathways, 
including stabilization of tumor suppressor protein p53 and release of cytochrome c  
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(Cyt c) from mitochondria [11]. Evidence of alternative death programs has emerged 
during the past few years, where it has become clear that chemotherapeutic compounds, 
including cisplatin, also can trigger, e.g., lysosomal membrane permeabilization, 
resulting in release of lysosomal proteins to the cytosol [12, 13]. However, intrinsic or 
acquired resistance to cisplatin is major limitations in use of this drug in cancer 
chemotherapy. Alterations in the expression of Bcl-2 family members during apoptosis 
can alter the sensitivity of the cells to apoptosis following cisplatin treatment. Thus 
higher concentration of drug might be effective in Bcl-2 overexpressing cells. It was 
reported that decreased Bax expression was observed in cisplatin resistant cells, 
whereas induced Bax expression sensitize the cells to cisplatin. However, it is clear that 
one of the cisplatin resistance responsible evidence is Bcl-2 and Bcl-xL over-expression 
[10]. Thus, cisplatin induced apoptosis mechanism should be further studied in in vitro 
and in vivo models to understand resistance mechanism related with different cell 
signaling pathways. 
2.1.2.2 Paclitaxel 
Over the last few years, breast cancer mortality has been steadily decreasing due 
to a variety of reasons, including the availability of newer cytotoxic agents. Among the 
most active newer agents, the taxanes, which target the microtubules, have emerged as a 
new cornerstone in the treatment of advanced breast cancer and, increasingly, of early 
disease as well [14]. Taxanes are natural products derived from trees of the genus 
Taxoidaceae. The first taxanes introduced in cancer therapy was paclitaxel, isolated 
from Taxus brevifolia [15, 16]. As well as paclitaxel, docetaxel is the most widely used 
agent in cancer therapy. These natural products have shown important clinical benefits 
in the adjuvant and in the metastatic setting, with objective response rates of 32 % – 68 
% when used as single agents [17]. However, this clinical success has been 
accompanied by significant side effects and primary as well as acquired (secondary) 
resistance. The mechanisms of resistance to taxanes are not fully understood and, as 
with many other agents, are likely to be multifactorial, including the overexpression of 
P-glycoprotein, the presence of β-tubulin mutations, and high microtubule-associated 
protein expression [14].  
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In earlier studies, the microtubule network appeared as the main target of 
paclitaxel. In fact, taxanes binds to β-tubulin subunits, thereby disrupting normal 
turnover of the microtubules [16]. The validation of the microtubules as a cancer target 
has led to the development of newer agents that target the microtubules. Microtubules 
play a fundamental role in diverse cellular functions such as cell division, growth, and 
motility, the development and maintenance of cell shape, and the trafficking of vesicles, 
organelles, and proteins. Microtubules are filaments formed with the polymerization of 
heterodimeric /ß tubulin subunits. A very complex dynamic process of polymerization 
and depolymerization is critical for microtubule homeostasis, which finally leads to the 
formation and functioning of the mitotic spindle. The taxanes interact with the tubulin 
units, resulting in alterations in the polymerization and depolymerization process. If this 
function is disrupted, a cell cycle arrest at the G2/M phase occurs, which in turn results 
in apoptosis [14]. Along with arrest in M phase of the cell cycle, taxanes have also been 
reported to induce post-translational serine phosphorylation of the Bcl-2 protein. 
Disagreement exists on the levels of Bcl-2 and resistance to taxanes [16]. A strong 
suggestion for a direct role of Bcl-2 in mediating paclitaxel sensitivity comes from 
observation that a cell line not expressing Bcl-2 is resistant to paclitaxel-induced 
apoptosis [18, 19]. Further support for this observation that paclitaxel is able to entrap, 
from a random peptide library, a panel of peptides showing a high degree of structural 
homology with disordered loop of Bcl-2, thereby indicating the latter as a motif for 
direct paclitaxel binding. In addition, it was shown that Bcl-2 or Bcl-xL over-expression 
protected ovarian cancer cells from paclitaxel-induced apoptosis. As well as other 
cellular signal molecules, Bcl-2 has a functional status in death machinery and 
modulation of Bcl-2 family members determines the cell fate following drug treatment 
[16]. Thereby, paclitaxel sensitivity should be discussed with all anti-apoptotic Bcl-2 
family members. Chemotherapy by microtubule-interfering agents is also limited by the 
emergence of drug resistance owing to mutations in the target, microtubules/tubulin, 
overexpression of drug efflux pumps, and many other mechanisms [18]. Taken together, 
despite the currently used treatment modalities, there is still no effective cure for 
patients with advanced stages of breast cancer, especially in cases of hormone-refractory 
cancer.  
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Therefore, the discovery and/or the development of drugs that combat hormone-
insensitivity and display better therapeutic indices would have an important effect on 
breast cancer morbidity and mortality [6]. 
2.2 Cell Death 
Apoptosis and necrosis are two morphologically distinct forms of cell death that 
are important for maintaining of cellular homeostasis [20-22]. Almost all agents can 
provoke either response when applied to cells; but the duration of treatment and the 
dose of the used agents determine which type of death (apoptosis or necrosis) is 
initiated. Necrosis occurs when cells are exposed to extreme variance from 
physiological conditions (e.g., hypothermia, hypoxia) which may result in damage to 
the plasma membrane. Under physiological conditions direct damage to the plasma 
membrane is evoked by agents like complement and lytic viruses. Necrosis begins with 
an impairment of the cell’s ability to maintain homeostasis, leading to an influx of water 
and extracellular ions. Intracellular organelles, most notably the mitochondria, and the 
entire cell swell and rupture (cell lysis). Due to the ultimate breakdown of the plasma 
membrane, the cytoplasmic contents including lysosomal enzymes are released into the 
extracellular fluid. Therefore, in vivo, necrotic cell death is often associated with 
extensive tissue damage resulting in an intense inflammatory response [20-22]. 
Apoptosis, in contrast, is a mode of cell death that occurs under normal 
physiological conditions and the cell is an active participant in its own demise (“cellular 
suicide”). It is also referred as programmed cell death which was first time described by 
Lockshin and Williams in 1964 [23]. It is most often found during normal cell turnover 
and tissue homeostasis, embryogenesis, induction and maintenance of immune 
tolerance, development of the nervous system and endocrine-dependent tissue atrophy. 
Cells undergoing apoptosis show characteristic morphological and biochemical 
features. These features include chromatin aggregation, nuclear and cytoplasmic 
condensation, partition of cytoplasm and nucleus into membrane bound-vesicles 
(apoptotic bodies) which contain ribosomes, morphologically intact mitochondria and 
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nuclear material. In vivo, these apoptotic bodies are rapidly recognized and 
phagocytized by either macrophages or adjacent epithelial cells. Due to this efficient 
mechanism for the removal of apoptotic cells in vivo no inflammatory response is 
elicited. In vitro, the apoptotic bodies as well as the remaining cell fragments ultimately 
swell and finally lyses. This terminal phase of in vitro cell death has been termed 
“secondary necrosis” (Table 2.1). 
Table 2.1 Apoptosis versus necrosis, biochemical and morphological features 
Morphological features 
 Apoptosis  Necrosis 
Outset Shrinking of cytoplasm and 
condensation of nucleus 
Swelling of cytoplasm and 
mitochondria 
Plasma membrane Blebbing of plasma membrane 
without loss of integrity  
Loss of membrane integrity 
Chromatin Aggregation of chromatin 
material in nuclear membrane 
 
Organelles Mitochondria become leaky due 
to pore formation involving 
proteins of the bcl-2 family. 
Disintegration (swelling) of 
organelles 
Vesicles Formation of membrane bound 
vesicles (apoptotic bodies) 
No vesicle formation, complete 
lysis 
Terminal Fragmentation of cell into 
smaller bodies 
Total cell lysis 
Biochemical features 
Regulation Tightly regulated process 
involving activation and 
enzymatic steps. 
Loss of regulation of ion 
homeostasis. 
Energy input Energy adenosine tri-phosphate 
(ATP)-dependent (active 
process, does not occur at 4°C) 
No energy requirement (passive 
process, also occurs at 4°C) 
DNA Non-random mono- and 
oligonucleosomal length 
fragmentation of DNA (Ladder 
pattern after agarose gel 
electrophoresis) 
Random digestion of DNA 
(smear of DNA after agarose 
gel electrophoresis) 
Timing Pre-lytic DNA fragmentation Postlytic DNA fragmentation  
(late event in cell death) 
Biochemical events Release of various factors 
(cytochrome C (Cyt c), 
apoptosis initiation factor 
(AIF)) into cytoplasm by 
mitochondria. 
Activation of caspase cascade. 
Alterations in membrane 
asymmetry (translocation of 
phosphatidylserine from the 
cytoplasmic to the extracellular 
side of the membrane) 
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Autophagy is an ancient mechanism by which starved cells produce energy and 
stave off death by gradually targeting their organelles and cytoplasmic elements to 
lysosomes for digestion. It is referred as lysosomal cell death or excessive self-
cannibalization [24]. It is a tightly-regulated process that plays a normal part in cell 
growth, development, and homeostasis, helping to maintain a balance between the 
synthesis, degradation, and subsequent recycling of cellular products. It is a major 
mechanism by which a starving cell reallocates nutrients from unnecessary processes to 
more-essential processes. 
A variety of autophagic processes exist, all having in common the degradation of 
intracellular components via the lysosome. The most well-known mechanism of 
autophagy involves the formation of a membrane around a targeted region of the cell, 
separating the contents from the rest of the cytoplasm. The resultant vesicle then fuses 
with a lysosome and subsequently degrades the contents. It was shown that deficient 
autophagic pathways result in cancer formation [21, 25]. 
2.2.1 Apoptosis 
Apoptosis, or programmed cell death, evolved in metazoans as a means to 
maintain tissue homeostasis by eliminating unwanted, damaged or infected cells in 
multicellular organisms. Apoptosis is very important step in body structure modeling 
during embryogenesis. As important as cell division and cell migration, programmed 
cell death allows the organism to tightly control cell numbers and tissue size, and to 
protect itself from rogue cells that threaten homeostasis. Therefore, it is an active 
process of cellular self-destruction with distinctive morphological and biochemical 
features. This type of cell death is classically defined by a pattern of molecular events 
and morphological changes, including condensation of cytoplasm, rounding up, loss of 
mitochondrial membrane potential, chromatin condensation to compact and simple 
geometric figures, nuclear fragmentation, blebbing with maintenance of membrane 
integrity (zeiosis) and finally loss of plasma membrane asymmetry, coupled to the 
display of phagocytosis markers on the cell (Table 2.1).  
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Apoptosis term originally comes from old Greek word which means the loss of 
petals and leaves in plants. The complicated process was discovered and rediscovered 
by cytologists and developmental biologists at several times during past 200 years and 
took several names. Finally the term adopted is apoptosis by Kerr and his collegues in 
1972 in order to describe a morphologically distinct form of cell death [26].  
Since the beginning of the 1990s, many human diseases have been associated with 
too much or too little apoptosis, such as degenerative diseases and cancer, respectively 
[27]. In their influential paper, Hanahan and Weinberg defined the ability to evade 
programmed cell death as a hallmark of most human cancers and pointed to the 
fundamental interplay between apoptosis and cell proliferation [20]. Impaired apoptosis 
mechanism also renders the tumor cell more resistant to conventional cytotoxic therapy 
[28]. Consequently, an attractive approach for anticancer therapeutics is to overcome 
this inherent resistance to apoptosis by directly activating the normal cell death 
machinery [29]. 
Two major apoptotic pathways through which caspases become activated in 
mammalian cells: the death-receptor pathway and the mitochondrial pathway. These 
apoptotic signaling pathways congregate at the mitochondria, where signals are 
processed through a series of molecular events ending in the release of potent death 
factors that trigger either caspase-dependent or -independent apoptosis.  
In fact, depends on the death signal type, apoptosis is regulated between three 
main parts of the cell. Plasma membrane is the starting point of receptor-mediated 
apoptotic pathway. Death stimulus starts when death ligands bind to the death receptor, 
resulting in their oligomerization. This leads to recruitment of adaptor proteins via death 
domain (DD) to the receptor. A C-terminus of adaptor proteins contains a death effector 
domain (DED), which interacts with pro-caspase-8, forming a complex called FLICE. 
Pro-caspase-8 is activated within this complex, and active caspase-8 can in some cells 
(type I) directly cleave and activate pro-caspase-3, which cleaves many structural 
proteins and proteins involved in DNA maintenance (e.g. by Inhibitor of caspase-
activated DNase (ICAD)). Upon this cascade of reactions, Caspase-activated DNase 
(CAD) is released and induces cleavage of DNA, resulting in nuclear apoptotic 
15 
 
morphology. In type II cells, caspase-8 is also capable to initiate mitochondria-mediated 
apoptotic signaling through cleavage of Bid with formation of truncated Bid (tBid) 
which interconnects death receptor pathway to mitochondria. The second place is 
mitochondria which covers energy metabolism within the cells. Mitochondria mediated 
pathway, the Bcl-2 family proteins are perhaps the most important key players. These 
proteins can also be responsible for bridging signals from the death-receptor pathway to 
mitochondrial pathway. The Bcl-2 family of proteins consist both anti-apoptotic and 
pro-apoptotic members. While pro-apoptotic members serve as sensors to death signals 
and executors of the death program, the anti-apoptotic members inhibit the initiation of 
the death program. The mitochondria-mediated apoptotic signaling might be triggered 
by diverse stimuli and resulted in release of several apoptogenic factors, i.e., 
cytochrome c, Smac/DIABLO, AIF, Endonuclease G, and Omi/HtrA2 from the 
intermembrane space of mitochondria into cytosol. This release is regulated by the Bcl-
2 family proteins. Bcl-2 and Bcl-xL block this process, whereas Bak and Bax promote it. 
Cytosolic Cyt c forms with Apaf-1 and pro-caspase-9 so called the apoptosome 
complex. As a result, pro-caspase-9 is activated and subsequently initiates the caspase 
cascade, including the activation of pro-caspase-3. The activation/activity of pro-
caspase-9 and -3 is inhibited by inhibitor of apoptosis protein (IAP), which in turn is 
regulated by Smac/DIABLO also released from the mitochondria. AIF and Endo G 
released from mitochondria translocate to the nucleus and cause chromatin 
condensation and DNA fragmentation. Heat shock proteins (Hsps) or Aven may block 
apoptotic signaling at several levels, including apoptosome formation, activation of 
caspases, and redistribution of Bid to mitochondria. Genotoxic stress inducers trigger 
nucleus. In this process, pro-caspase-2 is activated and involved in transducing the 
apoptotic signal from nuclei to mitochondria (Figure 2.2).  
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Figure 2.2 Cross-talk between plasma membrane, mitochondria, and nuclei in 
apoptotic signaling. Adopted from [30]. 
Accumulating evidence also shows other intracellular compartments and/or 
organelles such as the nucleus, the endoplasmic reticulum (ER), and the lysosomes all 
participate in apoptotic signaling [13, 30]. How the signals emerging from these 
organelles bifurcate into extrinsic and intrinsic apoptotic signaling pathways is of major 
importance for cancer therapy but has been only partly revealed as of yet. Therefore 
intensive research activity is required within the apoptotic field [30]. 
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2.3 Modulators of Apoptotic Signalling 
2.3.1 Caspases 
Programmed cell death depends on a family of aspartate-spesific cystein proteases 
(caspases) that cleave certain vital structural proteins such as lamins, gelsolin and 
preteolytically activate latent enzymes (nucleases) that contribute to cell destruction 
[31]. Of note, not all caspase family members participate in apoptosis. For example 
caspase-1 and caspase-11 are predominantly involved in the processing of pro-
inflammatory cytokines (interleukins 1 and 18) [32]. Their mechanistic action is first 
time described in Caenorhabditis elegans and well described in Drosophila 
melanogaster. Caspases are highly conserved through evolution, and can be found from 
humans all the way down to insects, nematodes and hydra. More than half number of 
identified caspases has been suggested to function in apoptosis [31, 33].  
Caspases can be divided into two groups with respect to their structure. Caspases 
with long pro-domain have structural motifs: caspase activation and recruitment domain 
or death effector domains. These domains provide interaction with other proteins. Short 
domain caspases such as caspase-3, 6, 7, 14 are activated by proteolytic cleavage by 
other caspases. The rest of fourteen identified human caspases belongs to long pro-
domain caspase subgroup. Caspases can also be grouped based on their function as 
apoptotic or inflammatory. The apoptotic group can be divided in two subgroups: 
initiator and effector caspases. Initiator caspases; caspase-2, 8, 9, 10, 12 activate 
effector caspases (caspase-3, 6, 7, 14) or indirectly interact through another pathway 
[29, 34]. Furthermore, as indicating before caspase-8 and caspase-10 are activated by 
death receptors in humans [35]. Contrary extrinsic pathway, mitochondrial pathway 
requires different initiator caspases and their adaptors; caspase-9 and its adaptor Apaf-1 
are involved in this pathway but not essential all cell types [36, 37]. Effector caspases 
are usually activated proteolytically by an upstream caspase, whereas initiator caspases 
are activated through regulated protein-protein interactions. The actual molecular 
mechanisms mediating initiator caspase activation are still unclear. 
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All known caspases possess an active-site cystein and cleave substrates at Asp-
Xxx bonds after aspartic acid residues. A caspase’s distinct substrate specificity is 
determined by four residues amino-terminal to the cleavage site [37]. Zymogens are the 
inactive form of caspases in healthy cells and they are activated through interaction with 
specific adaptor proteins that enhance conformational change and autocatalytic 
processing [31]. The inert zymogens are composed of three domains: an N-terminal pro-
domain, p20 and p10 domains. The mature enzyme is a heterotetramer which contains 
two p20/p10 heterodimers and two active sites. Thus they have two active sites (Figure 
2.3).  
 
Figure 2.3 Pro-caspase is cleaved at Asp X sites and result in active-caspase 
which contains two active sites. 
Caspases selectively cleave a limited set of target proteins, usually at one or at 
most a few positions in the primary sequence (always after aspartate residue). 
Moreover, they can indirectly activate a set of protein by cleaving off a negative 
regulatory domain or inactivating regulatory domain [37]. One decade ago, an important 
target was identified. Caspases was shown to activate nucleases which cut genomic 
DNA between nucleosomes, to generate DNA fragments [38]. Now, this approach is 
used for determination of apoptosis. DNA ladder nuclease CAD was shown as inactive 
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complex with an inhibitory subunit, ICAD in healthy cells. Activation of CAD occurs 
by caspase-3 mediated cleavage of the inhibitory subunit. Following cleavage, catalytic 
subunit released and then activated [39]. 
During apoptosis, caspases cleave nuclear lamins which are required for nuclear 
shrinking and budding. Moreover, in order to loss of cell shape, cytoskeletal proteins 
are cleaved. Finally, active blebbing is occurred following PAK2 cleavage which is a 
member of p21-activated kinase family. PAK2 activated by caspase-mediated cleavage 
of negative regulatory submit. Thus active blebbing is observed in apoptotic cells [37]. 
Mechanisms of caspase activation include proteolytic cleavage by an upstream 
caspase. Generally, activation of downstream, effector caspases is regulated by this 
way. It is probably also used for induction of apoptosis by non-caspase proteases, such 
as granzyme B. The second mechanism is recruitment of aggregation of multiple pro-
caspase-8 molecules into close proximity. The last proposed mechanism is activation of 
caspase-9 by means of conformational change, not proteolysis. Thus, holoenzyme 
formation, Cyt c and adenine tri-phosphate (ATP)-dependent oligomerization of Apaf-1 
allows recruitment of pro-caspase-9 into the apoptosome complex [37]. Of note, 
although it is clear that mitochondria membrane permeabilization (MMP) is involved in 
the activation of caspases, there has been considerable debate over whether MMP can 
occur independently of caspase activity [40]. It is clearly known that pro-caspase-8 
activation upon death receptor stimuli induces MMP by cleaving Bid into tBid [40, 41]. 
However, it was shown that in some cases caspase inhibitors could not prevent Cyt c 
release upon genetoxic stress induction. Although silencing of caspase-2 blocked Cyt c 
and Smac release from mitochondria following genotoxic stress inducers, caspase-2 was 
insensitive to pan-caspase inhibitors and directly evoke Cyt c and Smac release from 
isolated mitochondria. 
Furthermore, it was reported that loss of MMP, increased production of reactive 
oxygen species (ROS) and concominant lipid peroxidation and disruption of 
mitochondrial morphology by pan-caspase inhibitors. However, mutation studies 
showed that Cyt c release occurred normally in the presence of caspase inhibitors. 
These findings indicated that, Cyt c release occurred without disruption of respiratory 
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processes which indirectly supply ATP for various apoptotic processes while caspases 
are being activated in the cytosol. Following Cyt c release, caspases might enter 
mitochondria through partially permeabilized outer mitochondria membrane and shut 
down energy production to finalize apoptotic processes. Then sequentially, other 
intermembrane space proteins are released, ROS generation is induced and lipid 
peroxidation is increased for morphological disruption [40, 42]. 
2.3.2 Bcl-2 family proteins 
The integrity of mitochondrial outer membrane (MOM) is regulated by an 
evolutionary conserved group of proteins known as Bcl-2 family [27, 43]. Therefore, 
Bcl-2 family is central to both regulation and execution of most intrinsic apoptotic 
pathways. The Bcl-2 family proteins consists more than 30 different members that fulfil 
anti- or pro-apoptotic functions. All Bcl-2 family members hold at least one of four 
conserved Bcl-2 homology domains (BH1 to BH4). The family is comprised of three 
groups which are classified according to their content of BH-domains. To date, the 
human repertoire of multidomain members comprises six anti-apoptotic members (Bcl-
2, Bcl-xL, Bcl-w, Nrh/Bcl2l10/Bcl-B and Bfl-1) which contain four BH- domains, 
except Mcl-1 and Bfl-1/A1 [44], defined by their similarity among the members of the 
family. The pro-apoptotic Bcl-2 family is divided into the multidomain pro-apoptotic 
members (e.g. Bax, Bak, Bok) which contains BH1-3 domains, and the BH3-only pro-
apoptotic members (e.g. Bid, Bim, Bik, Blk, Hrk, Noxa, and Puma) (Figure 2.4).  
It seems that the so-called BH3-only molecules such as Bid, Bim and Bad are 
sensors for the peripheral death signals and are able to activate the multidomain 
executioner molecules, Bax or Bak [45]. BNIP is usually included into the BH3-only 
group based on its limited homology with BH3 domains [43]. Beclin, a Bcl-2 binding 
protein that promotes autophagy, and the cytosolic fragment of Erbb4 have also been 
proposed to be BH3-only proteins [46]. 
Most multidomain members and several BH3-only proteins contain a hydrophobic 
segment at their C-termini and this transmembrane domain (TM) is important for 
subcellular localization and/or activity. Some Bcl-2 family members such as Bcl-2 and 
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Bak are constitutively localized to the mitochondrial membrane, whereas others such as 
Bax and Bid reside in the cytosol and translocate to the mitochondria during apoptosis. 
It is worth highlight that Bcl-2 family members have been found in other organelles 
such as the ER and the nuclear envelope in addition to their localization in 
mitochondria. 
 
Figure 2.4 Schematic representation of three groups of Bcl-2 family members. 
(modified from [47]). 
2.3.2.1 Functional Bcl-2 homology  
Mutagenesis studies have revealed that BH-domains are important for the various 
molecular functions and for protein interactions among the family members. The BH1 
and BH2-domains are necessary for the death repression function of the anti-apoptotic 
molecules, and the BH4-domain has been suggested to be important for anti-apoptotic 
activity [48], BH3-domain is essential and sufficient for pro-apoptotic effect [49]. 
Despite opposite biological functions and wide differences in amino acid sequences, 
three dimensional (3D) structures and secondary structure predictions suggested that all 
multidomain Bcl-2 family members share a similar helical bundle structural fold, 
resembling the pore-forming domains of bacterial toxins. Based on this finding, at least 
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four members of Bcl-2 family members were determined to produce ion-conducting 
pores in synthetic lipid membranes in vitro [50]. This activity may relate to function of 
these proteins in regulating MMP.  
One of the major structural differences between multidomain proteins and BH3-
only proteins is that, a hydrophobic groove formed on the surface of anti-apoptotic Bcl-
2 proteins by the combination of their BH1, BH2 and BH3 regions is the binding site for 
the amphiphatic, α-helical BH3-domain of the pro-apoptotic family members. These 
findings suggest that BH3-only proteins may function as a donor in interaction with the 
multidomain proteins, whose hydrophobic of pocket can serve as an acceptor. BH3-only 
proteins, with the notable exception of Bid, have unrelated secondary structures and do 
not share pore forming helical bundle class [43, 47, 51]. The Bim was determined to be 
disordered in absence of interaction partners and to experiment a conformational change 
in its BH3 region upon binding to an anti-apoptotic member. In contrary, Bid is unique 
among the BH3-only proteins due to similarity to multidomain members of Bcl-2 
family. Different from other pro-apoptotic members, Bid interconnects death receptor 
apoptosis pathway to mitochondrial apoptosis pathway, and play important role in the 
control of cell cycle progression. Structural studies revealed that Bid has conserved 
structure before activation. However, activation of Bid by proteolysis can cause the 
exposure of its BH3-domain for its killing function. Contrary, the anti-apoptotic 
members usually have their BH3-domain buried, which may explain why they are not 
apoptotic. Recent findings showed that C-terminal of hydrophobic helix occupies the 
BH3-binding pocket. Therefore, displacement of the C-terminal tail from the 
hydrophobic groove is probably key event involved in the activation and targeting of 
Bax to the mitochondrial membrane upon apoptotic stimuli. The critical role of BH3-
domain as a mediator of cell death was also identified in studies on the molecular 
interactions between Bak and Bcl-xL, which revealed a unique requirement of BH3 for 
the interaction with Bcl-xL as well as for cell killing [49]. In the meanwhile, other pro-
apoptotic members were analyzed for their sequence similarity between their 
homologous domains were indentified and resulted in discovery of BH3-only proteins 
such as Bik/Nbk and Bad [52].  
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The anti-apoptotic members Bcl-2, Mcl-1, Bcl-xL, Bcl-w have similar overall 
structure as Bax and Bak, but with the exception of Mcl-1 and Bfl-1/A1 which contain a 
BH4-domain located toward their N-terminus [47]. Therefore structural studies are 
important to reveal their functional properties. Although, Bax was found very similar to 
Bcl-xL, it is not clear how Bax functions in opposition to the anti-apoptotic members. 
One clue from the structural study is that the full length Bax actually has a conformation 
similar to that of C-terminal-truncated Bcl-xL binding to a Bak BH3 peptide. The 
transmembrane domain of Bax is actually occupying its own hydrophobic pocket. It is 
known that Bax needs to change its conformation to be activated. Therefore solution 
structure is different in quiescent Bax than active Bax [47, 53].  
The other clue is that BH4-domain is directly involved in heterodimerization, but 
it may be decisive for the distinction between anti- and pro-apoptotic functions. Indeed, 
caspase-mediated cleavage of BH4 from Bcl-2 and Bcl-xL, thus the conversion of Bcl-2-
like proteins to Bax-like proteins, has been shown to result in Bcl-2 and Bcl-xL-derived 
pro-apoptotic forms [54]. It was shown that BH4-domain is being required for 
stabilization of MMP and Cyt c release [44]. The BH4-domain mediated anti-apoptotic 
activity was found independent from BH3-mediated heterodimerization [44]. 
2.3.2.2 The network of Bcl-2 protein family members-how does it work? 
Bcl-2 is the most famous member of the Bcl-2 family members and it was first 
described in 1984 by Tsujimoto et al. [55]. It was initially cloned from the t(14;18) 
breakpoint in human follicular lymphoma as a proto-oncogene and result in its up-
regulation. Since this discovery, many malignancies have been shown to overexpress 
Bcl-2 and other anti-apoptotic members. This overexpression results in constitutive 
block to Bax and Bak oligomerization, thereby preventing translation of the upstream 
death signals to outer mitochondria membrane permeabilization (MOMP). Although its 
proto-oncogene character was quickly realized, its biological function as an anti-
apoptotic gene was not realized until some years later [47, 53]. A number of proteins 
were soon discovered that share sequence homology with Bcl-2, but only some engage 
in anti-apoptotic activities; others actually promote apoptosis. The Bcl-2 family proteins 
are evolutionary conserved. Interestingly, a number of viruses were shown to be able to 
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encode Bcl-2 homologs. Most of these viral homologs are anti-apoptotic, probably 
because viruses need to keep the infected cells alive for latent and persistent infection. 
Perhaps the most understood pathway is that in the worm Caenorhabditis elegans, 
where detailed genetic studies have shown that two Bcl-2 related proteins anti-apoptotic 
CED-9, and a BH3-only death agonist, EGL-1 are essential for controlling 
developmentally programmed somatic cell deaths [56]. Expression of EGL-1, the death 
trigger, is induced by damage signals. Binding of EGL-1 to CED-9, the worm Bcl-2 
ortholog, releases the adapter protein CED-4 from CED-9. Once released, CED-4 binds 
to and activates caspase CED-3 to cause cellular demise [57].  
BH-domains of anti-apoptotic members seem to interact with the BH3-domain 
of pro-apoptotic members. The first identified pro-apoptotic Bcl-2 family member, Bax, 
was cloned based on its interaction with Bcl-2. The functional inhibition of Bax by Bcl-
2 relies, in part, in the ability of a hydrophobic cleft to bind to the conserved BH3 
domain of pro-apoptotic Bcl-2 members. The proposed interaction allowed that Bcl-2 
engages a group of pro-apoptotic Bcl-2 family members, the BH3-only proteins and 
prevent the BH3-domains of functional subset of proteins such as Bid, Bim by 
physically sequestering them from directly activating Bax. The directly interaction of 
these proteins with Bax, prevent it from exerting its deleterious effect on its activation 
by an apoptotic stimulus [58]. However interaction of proteins can be broken down by 
mutations which can occur at one of the domains.  
Previously it was shown that the regions outside of the BH-domain may be 
required for interactions, such as the interaction between BNIP1 and Bcl-xL [43]. 
Critical amino acids have been defined in each BH-domain, such as Gly145 in the BH1-
domain, Trp188 in the BH2-domain of Bcl-2, and Gly94 in the BH3-domain of Bid. 
Although Bcl-xL can bind to BH3-only and multidomain pro-apoptotic members, certain 
amino acids (Phe131 and Asp133) seem to be important for binding to BH3-only 
molecules, but not to Bax. Moreover, variations in certain key amino acids could result 
in different affinities in binding to the same molecule, which occurs with two Bcl-2 
isoforms in binding to Bak or Bad-derived BH3-peptides [27, 43, 57]. 
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Many other Bcl-2 family members were cloned based on this type interaction. A 
number of methods such as yeast-2-hybrid, co-immunoprecipitation and GST pull down 
assays were also utilized to find such interactions between pro-apoptotic and anti-
apoptotic members. However, identification of this kind of interactions is not easy in 
vitro conditions and should be proofed by in vivo experiments. Based on these analyses, 
several interaction types are defined [30]. These models also provide information how 
to BH3-only proteins activate Bax and Bak. Rheostat model focuses on the balance of 
anti-apoptotic and pro-apoptotic Bcl-2 proteins which determines the cellular fate. This 
mechanism is based on the assumption that the activities of pro-apoptotic Bcl-2 proteins 
are kept in check by the anti-apoptotic Bcl-2 family members, which are often 
permanent constituents of the mitochondrial membrane and which can bind and 
neutralize Bax and Bak. When any stress stimuli occurs, pro-apoptotic Bcl-2 proteins 
are induced or activated to trigger MOMP. In contrast, growth factors promote cellular 
survival by increasing the amount of anti-apoptotic Bcl-2 proteins or decreasing pro-
apoptotic members. For the interaction of Bcl-2 proteins, the BH3-domain seems to be 
required and binds into a hydrophobic pocket of anti-apoptotic Bcl-2 proteins [44, 59]. 
However, not all anti-apoptotic members can interact with all pro-apoptotic members. 
The selectivity between two kinds of proteins suggests that specific amino acids 
required for particular interactions may only exist in some but not all of the family 
members. The second type of interaction (neutralization model) is shown between two 
pro-apoptotic members, usually one BH3-only and one multidomain molecule (e.g. Bid 
to Bax or Bak) [44, 60]. According to neutralization model, BH3-only molecules 
directly bind to multi-domain anti-apoptotic members and neutralize their activity. This 
interaction leads to release of Bax and Bak. However the specificity of BH3-only 
proteins differs for each anti-apoptotic protein. For example, Noxa only binds Mcl-1 
and A1, and Bad engaged only Bcl-2, Bcl-xL and Bcl-w [61]. The last model is direct 
activation which is similar to neutralization model. According to this model, BH3-only 
proteins are functionally subdivided into activators and sensitizers [44]. Activation of 
Bax and Bak require direct association with activator BH3-only proteins. However, 
these proteins are normally bound and kept in check by anti-apoptotic Bcl-2 proteins. 
Bax and Bak are activated when activator BH3-only proteins are released from anti-
apoptotic Bcl-2 proteins through their binding to sensitizer BH3-only proteins (Figure 
2.5). These sensitizers cannot directly activate Bax and Bak. The main statement of the 
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last model is however still controversial as Bax and Bak were recently shown to 
mediate apoptosis also without association to BH3-only proteins. In Figure 2.5a, the 
indicated activator BH3-only proteins, via their BH3-domain (blue triangle), directly 
engage Bax and Bak and activate them, whereas sensitizer BH3-only proteins (e.g. Bad 
or Noxa), which can only bind the pro-survival proteins, serve only to displace 
activators from the pro-survival proteins. In the indirect activation model (Figure 2.5b), 
the BH3-only proteins only bind the pro-survival proteins. Because the promiscuous 
binders (Bim, tBid, and Puma) can neutralize all pro-survival proteins, each can readily 
trigger Bax/Bak activation, whereas any selective binder (e.g. Bad) must be co-
expressed with a complementary binder (e.g. Noxa) to do so. [59, 62]. 
  
Figure 2.5 Two models for how BH3-only proteins activate Bax and Bak. 
Modified from [59, 62]. 
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Furthermore, a number of cellular factors outside Bcl-2 family may also directly 
interact with Bcl-2 proteins to modulate their action. p53 can directly activate Bax and 
Bak, or block Bcl-2 and Bcl-xL, acting as an activator and de-repressor, respectively 
(Figure 2.6). p53 is found as mutated over half of cancer types. Therefore its 
transcriptional control is very important in normal cell behavior. A large number of pro-
apoptotic Bcl-2 family proteins and apoptosis related genes are regulated by p53. 
Among these proteins are Bax, Puma, Noxa, IGF-BP3, DR5/KILLER, Fas/Apo-1, the 
PIGs, PERP, Apaf-1 and p53-AIP. During apoptosis, some of these proteins translocate 
to mitochondria and promote release of mitochondria intermembrane proteins to the 
cytosol. Previous report showed that when recombinant p53 is added to mitochondria, 
results in Bak oligomerization and release of Cyt c. Moreover, it was shown that p53 
accumulation in cytosol was inefficient in Bax-/- knock-out mice models and treatment 
of purified mitochondria from Bak-/- MEFs with recombinant p53 did not induce Cyt c 
release [30, 63, 64]. 
 
Figure 2.6 The impact of p53 on the mitochondrial pathway in apoptosis. The 
trancriptional-independent and transciptional-dependent (Puma induction) 
functions of p53 are depicted (modified from [64]). 
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2.3.2.3 Functional regulation of BH3-only proteins 
There are main three types of regulation for BH3-only proteins at cellular level. 
First, selective phosphorylation of proteins at different residues might modulate 
different molecular and cellular responses. One of the example is that Bad 
phosphorylation on Ser-112, Ser-136 and Ser-155, which leads to the sequestration and 
inactivation of Bad by 14-3-3 proteins [65]. Moreover, phosphorylation of Ser-170 was 
shown to decrease pro-apoptotic activity of Bad [66]. The second factor is 
transcriptional control of BH3-only proteins. Puma and Noxa are transcriptional targets 
for p53 [67]. Puma is transcriptionally induced by the chemotherapeutics in a p53-
dependent or independent fashion (Figure 2.6). Puma is localized to mitochondria where 
it interacts with Bcl-2 and Bcl-xL. While the pro-apoptotic effect of Puma depends on 
Bax multimerization, induction of Noxa did not show any relevance to subcellular 
localization of Bax. Noxa selectively binds to Bcl-2, Bcl-xL and Mcl-1. The third 
regulation mechanism is cleavage. After death signal reception, the full length Bid (22 
kDa) is cleaved within its unstructured loop and a 15kDa truncated form of Bid is 
created, tBid [68]. tBid is selectively transferred to mitochondria and induces 
oligomerization of Bax and Bak. 
2.3.2.4 Pro-apoptotic Bcl-2 proteins trigger apoptosis independently of BH3-
domain 
Bcl-2 family proteins can interact with each other and also with several other 
proteins. However, increasing evidence indicates that pro-apoptotic function of Bcl-2 
proteins can also be independent of a functional BH3. Bok/Mtd is a structural homolog 
of Bax and Bak and predominantly detected in brain, liver and lymphoid tissues. While 
Bok/Mtd can bind Mcl-1 and Bfl-1 (but not Bcl-2 and Bcl-xL), Bax and Bak can not 
bind to these anti-apoptotic proteins. Mutational studies showed that BH3-mutant Bok 
can behave as a pro-apoptotic member [44, 69]. BNIP3 is structurally related to the 
BH3-only proteins. In normal cell, BNIP3 loosely associates with mitochondria and 
integrates deeper upon induction of cell death, while its N-terminus remains in 
cytoplasm. Complete deletion of BH3 could not diminish the killing activity of BNIP3 
not as same as other pro-apoptotic members. It act independent from Apaf-1, caspase-
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activation or Cyt c release but associated with an opening of the MMP. BNIP3 was 
shown as a critical for hypoxia-induced autophagy, and its expression and induction of 
autophagy upon hypoxia was blocked in hypoxia induced factor-1 (HIF-1) deficient 
cells [44]. Spike is a novel BH3-only protein but it is associated with endoplasmic 
reticulum instead of mitochondria and showed interaction with Bap31 protein. There is 
no evidence about its interaction with anti-apoptotic members but induce other pro-
apoptotic pathways. Hence it is independent of a BH3- mediated interaction [70]. 
2.3.2.5 Bcl-2 family members and mitochondria 
Mitochondria are also referred as a powerhouse or gatekeeper or gardens of cell 
death with dual function in survival and death decision. The recent evidence is that 
passive release of apoptotic molecules into cytosol upon MOMP. Moreover in many 
proposed scenarios MMP appears to have a better prognostic value for cell demise, than 
other events such as caspase activation which is induced by any of number of apoptotic 
insults, including ligation of death domain receptors, DNA-damaging agents, growth 
factor withdrawal or irradiation. It is not clear whether mitochondria can act as enhancer 
of caspase activity, or downstream caspases can contribute to Cyt c release or AIF 
release and loss of MMP.  
MMP is determined by two factors: outer membrane stability and inner membrane 
structure. If inner membrane partakes in outer membrane of mitochondria, a 
permeability transition pore (PTP) opens following by osmotic flux of water and 
molecules up to 1.5 kDa. Equilibration of ions between the matrix and cytoplasm 
occurs. PTP complex consists of adenine nuclear translocator in inner membrane, 
cyclophilin D in the matrix and VDAC and peripheral benzodiazepin outer membrane 
(Figure 2.7.). Sustained opening of PTP leads to MMP loss and osmotic swelling of the 
matrix, often sufficient to distort the structure of cristae and to rupture the outer 
mitochondrial membrane [63].  
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Figure 2.7 Structure of mitochondria. The translocator outer complex (TOM) is 
localized in the outer membrane and two translocases have been characterized in 
the inner membrane (TIM). VDAC: Voltage dependent anion channel, CK: 
creatine kinase, ANT: Adenine nuclear translocator, Cyt c: Cytochrome c, Cyc d: 
Cycline D. 
In spite of the exact process accounting for MOMP, three discernible and not 
mutually exclusive mechanisms were proposed to understand how cell death process 
occurs [63]: 
1. Release of mitochondria-residing factors that promote caspase-dependent 
(holocytochrome c, Smac/DIABLO and Omi/HtrA2) or caspase independent 
(AIF, Endonuclease G and Omi/HtrA2) cell death. This mechanism still is not 
clear. There are controversial studies whether these proteins are co-released 
during apoptosis. 
2. Loss of mitochondrial functions imperative for cell survival. It is well known 
that Cyt c hold a fundamental role in respiration, transfer of electrons from 
complex III to complex IV. Although mitochondrial damage is considered as 
the point of no return of death machinery, it is an accumulating process and 
not all or nothing phenomenon. When respiratory functions are disabled 
during early apoptosis can be overcome upon addition of exogenous Cyt c.  
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3. Generation of ROS. Mitochondria are the place for generation of ROS which 
leads lipid peroxidation, calcium mobilization, mitochondrial permeability 
transition, ATP depletion, protein oxidation, loss of electron transport and/or 
DNA damages. Their over-existence than required concentration triggers cell 
defense and the last death mechanism. Contrary, ROS can induce nuclear 
factor kappa B (NFκB) activation or inhibition of caspases to protect cells. 
The mitochondrial pathway is thought to be controlled by the relative balance of 
opposing Bcl-2 family members and their mutual interactions. However, despite 
extensive investigation, the precise biochemical mechanisms by which the three 
subgroups of Bcl-2 family members control mitochondrial apoptosis are still unclear 
[63]. BH3-only proteins function upstream of the multidomain proteins and act as 
sensors connecting multiple cytotoxic signals to the core apoptotic pathway. It was 
shown that Bax and Bak knock-out cells do not undergo MOMP and become resistant 
to various death stimuli. Mechanistically, Bax and Bak are thought to homooligomerize 
into pores in the MOM and cause Cyt c and other proteins release into cytosol [30, 63].  
In healthy cells, Bak is held in an inactive and it is placed into MOM at 
monomeric state thorough its association with VDAC-2. However, Bax may lay 
dormant in the cytosol through interactions with several proteins, including Ku-70, 14-
3-3 and humanin peptide [40, 71]. Following apoptotic stimuli, BH3-only protein 
dependent translocation of Bax is induced and then placed into MOM. Bax and Bak 
homooligomers are formed here and change the intermembrane space proteins 
conformation. Bcl-2 and Bcl-xL are localized on mitochondria and antagonize the 
functions of Bax, Bak and other BH3-only proteins. It was shown that increased 
association between Bcl-2 and Bak is observed following binding of tBid to Bak. 
Hence, it is proposed that Bcl-2 may play a role in regulation of Bax and Bak 
oligomerization. It is probable that anti-apoptotic proteins regulate mitochondrial 
apoptosis not only via interaction with BH3-only proteins, but also through 
heterodimerization with Bax and Bak and prevention of their insertion or/and 
oligomerization within MOM. Following this action, mitochondria outer membrane 
permeablized and intermembrane space proteins leak out. However, induction of 
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intermembrane space proteins occur one step before membrane permeabilization and 
these proteins differs upon upstream check point signals [40].  
Briefly, Bcl-2 family proteins are key regulators of the mitochondrial or intrinsic 
apoptotic pathway, including or preventing the release of Cyt c, AIF, Smac/DIABLO, 
Endonuclease G, translocates to the nucleus and causes oligonucleosomal DNA 
fragmentation, and Omi/HtrA2 that reside in the intermembrane space of mitochondria 
in healthy cells. Mitochondrial proteins cause caspase-dependent cell death include Cyt 
c which triggers caspase-9 activation by binding and activating the Apaf-1, and 
Smac/DIABLO, which potentiates caspase activation by binding IAP and blocking their 
caspase-inhibitory activity. However, the existence of a redundant molecule or 
molecules capable of compensating for the loss of Smac function has been suggested by 
gene deletion studies [62, 63].  
Instead of mitochondria, Bax, Bak and Bcl-2 can localize to the ER and can affect 
ER Ca2+ homeostasis and Ca2+ uptake by mitochondria which are regulating 
mitochondrial permeability transition pore formation and intermembrane space protein 
release. ER is normally an organelle wherein chaperone-assisted polypeptide folding 
and modification ensure the proteins obtain their mature conformation [30]. If unfolded 
protein number increases in ER, a conserved alarm system is activated and unfolded 
protein response (UPR) is triggered. UPR stop protein synthesis and increases ER 
localized chaperons, which allow the cells for correction. When the damage is severe 
and proper protein folding is not restored, unfold protein response triggers apoptosis 
[30]. It was shown that caspase-12 and caspase-4 primarily activated within the ER. 
Since mitochondria and the ER are interconnected physically and physiologically, it is 
very likely that apoptotic signaling, when initiated in ER, might relay to mitochondria. 
When the cells treated with ER stress inducers such as tunicamycin or brefeldin A, Cyt 
c is released and MMP occurs. These events block Bcl-2 localization in ER. Of note, it 
was shown that apoptotic response were not observed following in Bax and Bak 
deficient cells [30]. Bax and Bak deficiency were also characterized impaired Ca2+ 
release [30]. Recently, it is shown that ER-mediated stress activate Bim in two ways: 
enhanced transcription by CHOP(C/EBP) transcription factor and prevention of Bim 
ubiquination and degredation by protein phosphatase-2A [72]. This finding indicates 
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that ER pathway act predominantly upstream of mitochondria rather than through an 
independent path. However, more evidence is required to prove this fact. Hence, it is 
proposed that Bcl-2 proteins may activate various pathways in the mitochondria and ER 
during apoptosis [73].  
2.3.2.6 Atypical domain structures of pro-apoptotic Bcl-2 family proteins 
2.3.2.6.1 Bcl-rambo 
This atypical protein includes all four BH-motifs as well as the TM, but it was 
referred as pro-apoptotic protein. BH-domains of Bcl-rambo are separated from TM by 
a unique 250 amino acids long sequence with no relation BH-domains. The pro-
apoptotic function of Bcl-rambo is dependent on this sequence which works 
independently from BH-domains [44]. 
2.3.2.6.2 Bcl-G 
This protein encodes two pro-apoptotic proteins as a result of alternative splicing. 
The short one Bcl-Gs has similarities with BH3-only proteins, but long form, Bcl-GL is 
defined by a novel combination of BH3 with BH2 which is a repressing control domain 
of this protein. Mutational studies showed that when BH2-domain deleted, pro-
apoptotic function of Bcl-GL is enhanced [44]. 
2.3.2.6.3 Bfk 
This protein also contains BH3 with BH2-domain like Bcl-GL. It is found in 
cytosol not on organels. As Bcl-GL, Bfk does not bind to other Bcl-2 proteins. BH2-
domain again suppresses the pro-apoptotic function of BH3-domain of Bfk [74]. 
2.3.2.7 Alternative splicing of Bcl-2 proteins 
Several proteins in Bcl-2 family arise from alternative splicing, and many splice 
products are still waiting for characterization. There are also identified splicing products 
such as Bims, BimL, BimEL and Bax has eight splice variants with party deviating 
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domain structures. A well known is Bcl-x gene, which has four identified isoforms with 
different activities. Bcl-xL and Bcl-xES are anti-apoptotic, whereas Bcl-xS and Bcl-xAK 
are pro-apoptotic. Bim alpha and gamma were also shown in apoptotic process and still 
they are investigated to understand relations with other Bcl-2 family members. Recently 
two variants of Noxa is identified [75]. 
2.3.2.8 Targetting Bcl-2 Family Members 
The bcl-2 gene and other anti-apoptotic members of Bcl-2 family members are 
widely expressed in human cancers. Pathogenesis of disease and resistance to 
chemotherapeutics are linked with their over-expression. Several strategies either to 
reactivate pro-apoptotic Bcl-2 members or to suppress the anti-apoptotic ones have been 
developed with the aim of increasing anticancer treatment responses. Thus, modulation 
of pro-apoptotic members of the Bcl-2 family (mainly Bax and Bid) is becoming 
therapeutically relevant.  
2.3.2.8.1 Gene therapy and antisense oligonuclotides 
One current approach is delivery of Bax. Recombinant adenoviruses encoding for 
Bax are highly toxic, even to healthy cells. Although gene therapy tools need to 
optimization, Bax adenovirus transfected mice xenografts responded to therapy [76]. 
However till today, there are still problems with side-effects of gene therapy. 
Oblimersen (G3139, GC3139, oblimersen sodium) is an antisense oligonucleotide 
developed by Genta for systemic use as an injection. It comprises a phosphorothioate 
backbone linking 18 modified DNA bases. Oblimersen targets the first six codons of 
Bcl-2 mRNA to form a DNA/RNA complex. The duplex is subsequently recognised as 
a foreign message and is cleaved enzymatically, thereby destroying the Bcl-2 message. 
The Bcl-2 protein, which is a potent inhibitor of apoptosis, is overexpressed in many 
cancers, including follicular lymphomas, breast, colon and prostate cancers, and 
intermediate-/high-grade lymphomas. By reducing the amount of Bcl-2 protein in 
cancer cells, oblimersen may enhance the effectiveness of conventional anti-cancer 
treatments. Genta has reported results from randomised phase III trials of oblimersen in 
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four different indications: malignant melanoma, chronic lymphocytic leukemia, 
multiple myeloma and acute myleoid leukemia. However there are some negative 
opinions for indicated diseases therapy. Therefore drug is not approved for many of 
them in USA and European countries. Phase I and II trials are also underway or have 
been completed for a range of other cancer types. Overall in the clinical setting, 
oblimersen usually has statistically significant results but it has medically unimportant 
benefit. Therefore, the enthusiasm is diminished for the drug, especially when the side 
effects are re-considered. Specifically, the unmethylated CpG oligodinucleotides 
(and/or the phosphorothioate group) activates the immune system, but this potentially 
important anti-cancer effect is lost when the immune cells undergo premature apoptosis 
apparently because their Bcl-2 levels have been lowered by the antisense effect of 
G3139. While this effect on immune cells is usually undesirable, it is exactly what 
would be useful for activating immune cells, initiating provirus transcription in 
retrovirus-infected cells, and facilitating selective apoptosis of these infected cells. In 
general, G3139 might have benefit in clearing chronic infections by intracellular 
parasites including viruses (HIV, SIV, HTLV, HBV, coronavirus, etc.). Indeed, G3139 
has been shown to cause apoptosis in EBV-infected cells leading to clearance of the 
virus [77]. 
2.3.2.8.2 RNA interference strategy to down-regulate Bcl-2 protein levels 
A recent technology based on RNA interference (RNAi) is selectively and 
postranscriptionally block homologous gene expression, and it has revolutionized 
approaches in the study of gene function. RNAi is considered to have begun as an 
evolutionarily ancient mechanism for protecting organisms from viruses. Many viruses 
have RNA, rather than DNA, as their genetic material and go through at least one stage 
in their life cycle in which they make double stranded RNA. Perhaps not surprisingly, 
all multicellular organisms have evolved a well conserved protein apparatus that 
destroys double stranded RNA but this has also been found to play a role in 
maintenance of the organism’s own genome stability by suppressing the movement of 
mobile genetic elements, such as transposons and repetitive sequences [78]. 
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Briefly, explanation of RNAi is that a double stranded RNA (dsRNA) introduced 
or naturally expressed in a cell and triggers posttranscriptional gene silencing which 
results in degredation of specific mRNA target [79].  
A ribonuclease III, Dicer, is activated on dsRNA and convert it to short interfering 
RNA (siRNA). siRNA molecules are generally 21-27 nucleotides long. RNA inducing 
silencing complex (RISC) cleaves target mRNA which has a complementary region to 
the siRNA sequence. Each sequence has a 5’ phosphate group and a 3’hydroxyl group. 
Although systems can produce siRNA molecules in vivo, these molecules can be also 
exogenously introduced into cells by various transfection method to bring about the 
specific knock-down of a gene interest. However, artificially introduction of specific 
siRNAs into cells can be problematic due to transient knock-down efficiency. One way 
of overcoming this challenge is to modify the siRNA in such a way as to allow it to be 
expressed by an appropriate vector. This is done by the introduction of a loop between 
the two strands, thus producing a single transcript, which can be processed into a 
functional siRNA [79].  
However, applying RNAi via siRNAs to living animals, especially humans, poses 
many challenges. Experimentally, siRNAs show different effectiveness in different cell 
types in a manner as yet poorly understood: some cells respond well to siRNAs and 
show a robust knockdown, whereas others show no such knockdown (even despite 
efficient transfection). 
Given the ability to knock down essentially any gene of interest, RNAi via 
siRNAs has generated a great deal of interest in both basic and applied biology. There 
are an increasing number of large-scale RNAi screens that are designed to identify the 
important genes in various biological pathways. Because disease processes also depend 
on the activity of multiple genes, it is expected that in some situations turning off the 
activity of a gene with an siRNA could produce a therapeutic benefit. 
Further studies demonstrated that Bcl-2 siRNA enhances the cytotoxic and 
apoptotic effect of conventional chemotherapeutics such as etoposide and doxorubicine 
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in MCF-7 breast cancer cells. In vivo studies showed that following Bcl-2 siRNA 
treatment, tumor volume and growth were diminished. 
Recently in addition to siRNA, RNAi can also involve small RNA-mediated gene 
silencing via microRNA (miRNA). Contrary to siRNA, miRNAs are coded by 
endogeneous genes. miR-15 and miR-16 were shown to down-regulate Bcl-2 and 
triggered apoptosis. Interestingly, these miRNAs were frequently deleted or down-
regulated in chronic lymphoid leukemia. Therefore, extend research would be helpful to 
understand their functional properties in apoptosis machinery with other genes which 
are directly or indirectly involved in the control of apoptosis [80]. 
2.3.2.8.3 Synthetic BH3-mimetics or peptide-based Bcl-2 targetting 
According to the Bcl-2 activation models, BH3-only members of the Bcl-2 family 
bind to anti-apoptotic members, counteracting their protective effect by freeing 
multidomain proapoptotic members Bax and Bak. Therefore BH3-only proteins have 
become an attractive strategy for the development of new anti-cancer therapies. Their 
small structure (14-24 amino acids) can be easily synthesized as peptides or 
pharmacological active small molecules. 
It is apparent that overexpression of BH3-only molecules induce apoptosis. 
Recently it was shown that soluble BH3-peptides produce Cyt c release from isolated 
mitochondria [22, 81]. Their enhanced stability and easy entrance to cells is promising 
for potential use in cancer therapy as therapeutic tools. For example, stapled BH3-
peptides with enhanced stability like BID-SAHB peptide which is derived form of Bid 
enhance apoptosis in Jurkat cells and inhibit xenograft growth in leukemia models. A 
Bad-BH3 peptide with a high cell permeable moiety induces apoptosis in HL-60 
leukemia cells in a caspase dependent way and delayed growth of myeloid leukemia in 
mice models. These findings show that BH3-peptides are promising in cancer therapy 
models [82]. 
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2.3.2.8.3.1 ABT-737 
Computer analysis has lead to discovery of BH3-mimicking small compounds 
which bind to the hydrophobic groove in the surface of anti-apoptotic proteins. One of 
leading compound is ABT-737 (Abbott Laboratories, USA) was identified using nuclear 
magnetic resonance (NMR)-based screening tool. ABT-737 potently inhibits the Bcl-2, 
Bcl-xL and Bcl-w but not Mcl-1 or A1/Bfl-1 [83]. It was shown that ABT-737 is a 
functional Bad-BH3-mimetic but it is not structural similar to Bad-BH3-domain. 
Therefore its anti-apoptotic function is not sufficient but it has synergistic potential with 
other drugs. It is worthy to underline that ABT-737 is not efficient in normal cells but 
enhance the apoptotic effect of other drugs in malign cells [81, 83].  
2.3.2.8.3.2 Obatoclax (GX15-070) 
Obatoclax is a BH3-mimetic and a derivative of indol bipyrrol (Gemin-X 
Biotechnologies, Canada). In contrast to ABT-737, obatoclax seems to be a pan Bcl-2 
inhibitor that which is a target of Mcl-1. It has high efficiency in hematological 
neoplasmas, breast cancer and even in cells that are resistant to melphalan, ABT-737 or 
bortezomib. Recently, it is being tested in Phase I clinical trials, alone or in combination 
with bortezomib, docetaxel, topotecan or rituximab in patients with relapsed or 
refractory mantle cell  lymphoma, chronic lymphocytic leukemia, non-small lung 
cancer and other solid tumors [84, 85]. There are also Phase II trials in patients with 
Hodgkin’s lymphoma, myelofibrosis with myeloid metaplasia, myelodysplasia and 
follicular lymphoma. Obatoclax can also distupt the Mcl-1/Bak interaction [84, 85]. 
However there is no structural proof of obatoclax binding in the hydrophobic groove of 
anti-apoptotic Bcl-2 family proteins [53]. 
2.3.2.8.3.3 HA14-1 
Ethyl 2-amino-6-cyclopentyl-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromone-3-
carboxylate (HA14-1), the first reported small molecule antagonist for Bcl-2 protein, 
was identified by Wang et al. [82]. This simple chemical structure is a putative Bcl-2 
inhibitor, which was identified from in silico screens [86]. HA14-1 disrupts the binding 
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interaction of the Bak BH3 domain peptide with Bcl-2 and Bcl-xL proteins [82] strongly 
inhibits the Bcl-2/Bax interaction [87] and prevents the interaction between Bcl-2 and 
the BH3-only protein Bim [88]. Since its discovery, HA14-1 has been shown to enhance 
the cytotoxic effects of variety of anticancer agents (Figure 2.8). 
HA14-1 involves changes in Ca2+ homeostasis, inhibition of mitochondrial 
potential, Bax translocation, reactive oxygen species generation (ROS), cytochrome c 
release and caspase-9/-3 activation, and subsequently poly(ADP-ribose) polymerase 
(PARP) cleavage [82, 89, 90]. The therapeutic effect of HA14-1 has been described in a 
variety of tumor cells. HA14-1 cooperates with other drugs such as flavopiridol, 
bortezomib, dexamethasone, doxorubicin and cytrabine [91, 92]. Additionally, HA14-1 
could potentiate non-toxic MAPK inhibitors as lethal agents in the cell culture 
environment [93]. Although these results indentify HA14-1 as a good candidate for anti-
cancer treatment, some concerns have been recently raised about this compound [94]. 
First, it is very unstable and decomposes very rapidly under physiological conditions. 
Second, although the biological activity of HA14-1 was supposed to depend on its 
interaction with Bcl-2, recent findings show that ROS generation could be main reason 
of cell death induced by this compound [53].  
 
Figure 2.8 The structure of HA14-1 bound to the surface pocket of Bcl-2 as 
predicted by computer docking studies. Adopted from [86]. 
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2.3.2.8.3.4 TW-37 
Recently, a small molecule pleiotropic BH3-mimetic, TW-37 was designed with 
high affinity to Mcl-1 in addition to Bcl-2 and Bcl-xL. Since TW-37 discovery, there 
was no effective synthetic inhibitor for Mcl-1. TW-37 and a MEK inhibitor 
synergistically killed aggressive melanoma cells with minimal toxicity for normal skin 
cells [95]. In addition, preclinical studies suggest that the combination of TW-37 and 
cyclophosphamide-doxorubicin-vincristine-prednisone may be promising in the 
treatment of diffuse large B cell lymphoma [96]. 
2.3 Reactive oxygen species and mitochondria 
Mitochondria are an important source of ROS within most mammalian cells. 
This event contributes to mitochondrial damage in a range of pathologies and is also 
important in redox signalling from the organelle to the rest of the cell [97]. Recent 
knowledge about how mitochondria produce ROS is vital to understand a range of 
currently important biological and biomedial topics. The first report about ROS 
production due to respiration at mitochondria was shown in 1966 [98]. Following this 
discovery, Chance and colleagues showed that isolated mitochondria produce H2O2 
[99]. Later, it was confirmed that this H2O2 arose from the dismutation of superoxide 
(O2•−) generated within mitochondria . The parallel discovery that mitochondria contain 
their own superoxide dismutase, MnSOD, confirmed the biological significance of 
mitochondrial O2•− production [100]. Within mitochondria, O2•− is produced by the one-
electron reduction of O2. Therefore it is the kinetic and thermodynamic factors 
underlying the interaction of potential one-electron donors with O2 that control 
mitochondrial ROS production [97]. 
Intracellular generation of ROS per se is an inevitable (and sometimes 
physiologically important) process. To counter it, mitochondria, and cells in general, 
possess numerous ROS defense systems. It should have been implicit that the true 
source of oxidative stress is not the ROS generation per se but spatiotemporal 
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imbalance of ROS production and detoxification, and, yet, until recently, even the 
capacity of mitochondrial ROS defence was unknown.  
In fact ROS are not all accidental and unwanted byproducts. This cellular process 
orchestrate many critical events in the cells. One of the main event is the modulation of 
cell death decision. Mitochondria is one of the central place which regulate cell death 
and survival decision under the control of Bcl-2 family members. Excessive production 
of ROS is a typical sign of apoptosis. Thus, numerous studies have documented cellular 
changes resulting from oxidative stress induced in cells following exposure to cytotoxic 
drugs. Although cytotoxic agents such as doxorubicin, daunorubicin, mitoxantrone, 
bleomycin and cisplatin used in these studies were structurally dissimilar and acted on 
different cellular targets, they induced oxidative stress by generation of ROS in tumour 
cells. Formation of ROS increased the cytotoxic activity of the drugs in cancer cells via 
inducing apoptosis [101].  
The sustained mitochondrial inhibition due to apoptotic induction would also 
potentiate ROS formation, leading to the depletion of antioxidant defenses (thiols such 
as gluthation) and initiation of lipid peroxidation. Lipid peroxidation could cause 
structural damage to membranes, including those which form mitochondria, and 
potentiate their dysfunction. This sequential process can modulate several proteins and 
structures to finalize cell death decision. H2O2 generation which triggers ROS 
generation and lipid peroxidation was contributed to apoptosis induced by physiological 
concentrations of several drugs. Therefore, there are a number of studies supporting the 
hypothesis oxidative stress might modulate the cytotoxicity of several cytotoxic agents. 
However, the mechanisms by which ROS mediate the apoptotic effect of drugs and the 
identity of specific ROS involved in the process are unclear [101]. For example, the role 
of specific ROS and antioxidant systems in the regulation of Bcl-2 and apoptosis 
induced by drugs are need to be clarified. Previous studies have shown that O2- plays a 
role in Bcl-2 regulation. Downregulation of superoxide dismutase by antisense gene 
inhibition decreases Bcl-2 expression and increases cell death induced by cisplatin 
[102]. Since superoxide dismutase acts by dismutation of O2•- to form H2O2 and since 
H2O2 is a major source of OH• production, i.e., via Fenton-like reactions, it is possible 
that other oxidative species may play a role [103]. It was proposed that H2O2 may be a 
common regulator of Bcl-2 expression under diverse pathologic and treatment 
conditions. Since aberrant expression of Bcl-2 has been associated with several human 
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cancers, our findings on the regulatory mechanism of Bcl-2 by ROS could be important 
in the understanding of carcinogenesis and in the development of novel therapeutic 
strategies that could overcome cancer chemoresistance. 
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CHAPTER 3 
 
 
 
 
 
 
3 MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Chemicals, media components and antibodies 
Chemicals, media components and antibodies that are used are listed in Appendix 
A. 
3.1.2 Molecular biology kits 
Molecular biology kits which are used for cell viability determination, apoptosis 
screening, gene transfection, RNAi transfection, and protein analysis are listed in 
Appendix B. Other special materials including DNA, RNA and protein markers are 
indicated in Appendix C. 
3.1.3 Equipment 
Equipment that is used for general laboratory purposes are listed in Appendix D. 
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3.1.4 Buffers and solutions 
Standard buffers and solutions used in cloning and molecular manipulations were 
prepared according to the protocols in Molecular Cloning: A Laboratory Manual [104]. 
3.1.4.1 Buffers for nucleic acid isolation 
Buffer A for agarose gel electrophoresis 
1X Tris EDTA acetate (TAE) buffer was used for preparation of 1.5 % agarose 
gels. Gels were run at 100 mV for 30 minutes. DNA was visualized by including 0.005 
% ethidium bromide. 
Buffer B for agarose gel electrophoresis 
1X Tris Borate EDTA (TBE) buffer was used for 2 % agarose gel electrophoresis. 
Gels were run at 80 mV for 60 minutes. RNA was visualized by including 0.005 % 
ethidium bromide. 
3.1.4.2 NP-40 lysis buffer for M30 Apoptosense ELISA assay 
150 mM NaCl, 1 % NP-40, 50 mM Tris-HCl were dissolved in ddH2O. pH was 
adjusted at 8.0, and buffer was stored at -20oC. 
3.1.4.3 Buffers for immunoblotting 
10 X PBS (Phosphate Buffered Saline) 
80 g NaCl, 2.25 g KCl, 23.27 g Na2HPO4.12H2O and 2.05 g KH2PO4 were 
dissolved in 1000 ml ddH2O of and pH was adjusted to 7.4.  
10 X TBS (Tris Buffered Saline) 
87.7 g NaCl, 12,1 g  
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Tris, 4 ml HCl were dissolved in 1000 ml ddH2O of and pH was adjusted to 7.4. 
1 X TBS-Tween-20 
10 X TBS was diluted, 0,2 % Tween-20 was added and pH was adjusted to 7.4. 
1 X PBS-Tween-20 
10 X PBS was diluted, 0.2 % Tween-20 was added and pH was adjusted to 7.4 
10 X Running Buffer 
250 mM Tris base, 1.92 M glycine and 1 % (w/v) SDS were dissolved in 500 ml 
ddH2O and pH was adjusted to 8.5. 
Buffer for SDS polyacrylamide gel electrophoresis 
1 X running buffer was prepared from 10 X stock solution and was used for 
polyacrylamide gel electrophoresis. Gels were run at constant voltage 75 mV, for about 
1.5 h. 
 4 X Tris-Cl/SDS pH 6.8 
 0.25 M Tris and 0.2 % SDS (w/v) were dissolved in 50 ml ddH2O. pH was 
adjusted to 6.8  
 4 X Tris-Cl/SDS pH 8.8 
 0.75 M Tris and 0.2 % SDS (w/v) were dissolved in 50 ml ddH2O. pH was 
adjusted to 8.8. 
10 X Transfer Buffer 
0.25 M Tris Base and 1.92 M glycine was dissolved in 500 ml of ddH2O.   
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3.1.4.4 Buffers for transfer of proteins into PVDF membrane 
1 X transfer buffer was prepared by dilution from 10 X stock solution and 20 % 
methanol addition prior to the blotting of the proteins into PVDF membrane. The 
membranes were blocked with blocking solution, 5 % milk powder in 1X P(T)BS-
Tween-20 and washed with washing buffer 1X P(T)BS and 1X P(T)BS- Tween-20. The 
antibodies were diluted in 5 % milk diluent in 1X P(T)BS- Tween-20.  
3.1.4.5 Stripping Buffer 
62.5 mM Tris-HCl and 2 % SDS (w/v) were dissolved in 500 ml ddH2O and pH 
was adjusted to 6.7. Prior to use 352.1 µl of β-mercaptoethanol was added for each 50 
ml of solution.  
3.1.5 Growth media 
Mammalian breast cancer cell lines; MCF-7 (HTB-22) and MDA-MB-231 (HTB-
26) were cultured in RPMI 1640 supplemented with 10 % heat inactivated fetal bovine 
serum (FBS), 2 mM glutamine, 100 UI/ml penicillin and streptomycin. Cultures were 
maintained in 37°C in a humidified 5% CO2 atmosphere. Bcl-2 plasmid inserted MCF-7 
and MDA-MB-231 cell line were maintained in the same medium formula 
supplemented with antibiotic G418. 
3.1.6 Freezing media 
The cells were kept in freezing medium which containing FBS and 10 % di 
methyl sulfooxide (DMSO) at -80°C for 24 h and then kept in liquid nitrogen. 
3.1.7 Plasmids and primers 
Bcl-2 plasmid was provided by Dr. O. Kutuk (Addgene plasmid 8768) and used 
for stable transfection (Figure 3.1) 
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Figure 3.1 Bcl-2 pCI DNA3 plasmid vector map. ORF contains SacI, PstI and 
BamHI sites for T7 direction [105]. 
Bcl-2 (Qiagen, Gene globe, QT00025011), Bax (Qiagen, Gene globe, 
QT00031192), Bcl-xL (Qiagen, Gene globe, QT00236712), Puma (Qiagen, Gene globe, 
QT00082859) and Noxa (Qiagen, Gene globe, QT01006138) were primers sets. 
GAPDH (Qiagen, Gene globe, QT01192646), 18s RNA (Qiagen, Gene globe, 
QT00199367) and β-actin (Gene globe QT00199367) were used as internal standard 
gene primer sequences. 
3.2 Methods 
All methods used in this study are explained below; 
3.2.1 Cell culture 
MCF-7 (HTB-22) and MDA-MB-231 (HTB-26) breast cancer cells were obtained 
from American type of cell collections (ATCC, LGCpromochem, UK). The Bcl-2 
plasmid transfected stable MCF-7 cell line was obtained from Dr. Ozgur Kutuk.  
When cells were grown to confluency, subculturing to a new passage numbers 
was done with filter-sterilized 1X trypsin-EDTA solution. As soon as cells were 
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detached in 37°C CO2 incubator, medium containing serum is added to inhibit further 
trypsin activity that might be harmful for cells. Cells were counted with a 
haematocytometer by the following formula: 
cells/ml = average count per square X dilution factor X 104 
MCF-7 and MDA-MB-231 breast cancer cell lines were splitted in every 2-3 days 
and equal volumes of each cell line were passaged to new flask or petri dishes in 
appropriate seeding densities. Cells were seeded in 96 well plates (1x104 cells/well), 6 
well plates (4x105 cells/well) and treated as indicated in the experimental protocols. 
Bcl-2 plasmid inserted MCF-7 and MDA-MB-231 cell lines were splitted in every 5-7 
days by the same procedure as indicated above.  
For the preparation of frozen stocks, each cell line at log phase growth (50-75 % 
confluency), was trypsinized, spinned down at 300 g for 5 min and washed with sterile 
1X PBS. Again cells were spinned down at 300 g for 5 min and were transferred into 
cryovials. Cryopreservation of cells should be slowly freeze starting from 1 h at -20°C 
and then frozen at -80°C for 24 h and then kept in liquid nitrogen to remain until 
thawing. After thawing the cells were immediately washed with growth medium to get 
rid of DMSO 
3.2.2. Cell viability assay 
Cell viability was determined using MTT Proliferation kit (Roche, Germany) 
which is based on the conversion of MTT to MTT-formazan by mitochondrial enzymes. 
Each cell line was seeded into 96-well plates (1x104 cells/well) and treated as indicated 
experimental scheme. 10 µl MTT labeling reagent was added to each well, after which 
the plates were incubated for 4 h. The cells were then incubated in 100  µl of the 
solubilization solution for overnight, and the absorbance was measured with a microtiter 
plate reader (Bio-Rad, USA) at a test wavelength of 550 nm and a reference wavelength 
of 650 nm.  
Percent (%) viability = OD of drug-treated sample/control X 100 
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3.2.3 M30 Apoptosense ELISA assay 
Cytokeratin-18 (CK18) cleavage indicates the activation of caspases and was 
measured using reagents from Peviva AB. MCF-7 and MDA-MB-231 breast cancer 
cells (1x104 cell/well) were seeded on 96-well plates. A solution of 10 % NP-40 was 
added and mixed for 5 min at room temperature. Two replicates of 25 µl cell 
lysate/medium were transferred into a specific M30 Apoptosense ELISA assay. This 
assay was performed according to the manufacturer’s instructions. After the washing 
step, stop solution was added to each well, and samples were incubated in the dark for 5 
min. The spectrophotometric measurement was made at 450 nm. Absorbance data was 
converted to U/L according to standart curve plot analysis. 
3.2.4 Mitochondria membrane potential loss 
Mitochondria membrane potential loss was measured using rhodamine 123, a 
green fluorescent dye that accumulates in active mitochondria with high membrane 
potential. 4x105 cells were seeded into 6 well-plates. Following drug treatment, washed 
with 1 X PBS twice times. Cells were loaded 5 mM rhodamine 123 in 1X PBS for 30 
min at 37oC. Then the cultures were washed three times with 1X PBS. Rhodamine 123 
was excited at 488 nm and fluorescence emission at 525 nm was recorded. Samples 
were also investigated by fluoresence microscopy (Olympus IX70) at green filter [106]. 
3.2.5 Colorimetric caspase-9 activity determination 
Caspase-9 activity was determined using ApoTarget Caspase Colorimetric 
Protease Assay Sampler Kit (Invitrogen, KHZ1001). 4x105 cells were seeded into 6-
well plates. Following drug treatment, cells lysate were mixed with 50 µl cell lysis 
buffer, supplied in kit. Samples were kept on ice for 10 min. Protein content was 
determined by Bradford Assay [107]. Each sample diluted with cell lysis buffer to 
obtain 2 mg/ml protein concentration. Each sample mixed equal volume of reaction 
buffer 2 X. 4 mM caspase-9 subtrate (final concentration 200 µM) was added into 
sample and mixed at 37oC for 2 h. Samples were transferred to microtiter plates and 
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read at 405 nm absorbance. Caspase-9 activity was determined fold comparison of 
treated samples to untreated sample. 
3.2.6 RNA isolation 
Total RNA content was isolated using a TRIzol reagent (Invitrogen) following the 
procedure described by the manufacturer. Total RNA was digested with RNase-free 
DNase (Boehringer Mannheim, Indianapolis, USA) for 15 min at 37oC. 
3.2.7 Reverse transcriptase (RT) reaction 
Reverse transcription (RT) was performed using a specific RT kit (Qiagen, 
Germany). The RT reaction mixture contained 1 µl of total RNA, 500 ng of oligo(dT) 
primer, 5 X RT reaction buffer, 10 mM dNTPs, and 200 U of a reverse transcriptase in a 
total volume of 20 µl. The all samples were incubated in 37°C for 1.5 h. The quantity of 
cDNA was calculated using spectrophotmetry by determination of optical density at 260 
nm (OD260). Purity was calculated using OD260/280 ratio.  
3.2.8 RT-polymerase chain reaction 
Real-time PCR was performed in 96-well 0.2 ml thinwall PCR plates (Bio-Rad, 
USA) using the iCycler Thermal Cycler (Bio-Rad, USA) and carried out with 
QuantiTect SYBR Green PCR Master Mix (Qiagen, Germany), which contained 
HotStarTaq DNA Polymerase, QuantiTect SYBR Green PCR Buffer, and SYBR Green 
I. The real-time PCR reaction mixture contained 1 X QuantiTect SYBR Green PCR 
Master Mix, 0.3 mM primer pairs, and 500 ng cDNA in a total volume of 25 µl. The 
mixture was heated initially at 95°C for 15 min in order to activate HotStarTaq DNA 
Polymerase and then followed by 40 cycles with denaturation at 94°C for 1 min, 
annealing at 54°C for 1 min, and extension at 72°C for 1 min. Furthermore, the number 
of amplified products was identified by melt curve analysis. The melt curve protocols 
designed for increment temperatures of 0.5°C with a starting temperature of 54°C and 
ending at 90°C were repeated to ensure that primer dimers and other nonspecific 
products had been minimized or eliminated. 
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3.2.9 Data expression 
Standard curves constructed from serial dilution of a known number of PCR 
product molecules were analyzed with the iCycler iQ Real-Time PCR Detection System 
(Bio-Rad, USA). The baseline was set automatically by the software using data 
collected from cycles 2 to 10, and the threshold cycle (Ct) at which the amplification 
plot crossed the baseline was calculated. The raw abundance values for each gene was 
divided by the standard housekeeping genes (18sRNA/GAPDH/β-actin) values obtained 
from the same samples to derive a normalized value for each sample. In preliminary 
experiments, standard housekeeping gene mRNA levels within a sample were constant 
between individual treated study materials 
3.2.10 Transfection of siRNA 
MCF-7 and MDA-MB-231 cells were placed in a six well plate 24 h prior to 
transfection. Approximately 4 x 105 cells/well were transfected with 20 nM Hs_Bcl-
2_9_siRNA (Gene Globe, Qiagen) in 6-well plates. According to manufacturer 
instructions 1:9 and 1:6 siRNA-transfection reagent complex were used in MCF-7 and 
MDA-MB-231 cells, respectively. After 48 h incubation, the silencing effect was 
checked with qRT-PCR and western blot analysis [108]. 
3.2.11 Plasmid isolation 
Plasmid DNA was transformed to competent cells (E. coli, DHα) and plasmid 
DNA was prepared with MidiPrep kit. Starting culture with 2 ml LB broth containing 
antibiotic ampicillin (100 mg/ml) was inoculated with a single transformant colony. 
After growth at 37ºC for 8 h with vigorous shaking (250-270 rpm), 1/500 of this culture 
was inoculated into a larger culture (50 ml) and continued grow for 12-16 h at 37ºC 
with vigorous shaking. According to manufacturer instructions, plasmid DNA was 
prepared (MidiPrep, Qiagen). The quality and quantity / concentration  of the plasmid 
DNA were checked by agarose gel electrophoresis (1 % agarose gel 1 X TAE) and 
spectrophotometry (absorbance at 260 nm with A260/280 ratio close to 1.8) [104] 
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3.2.12 Stable transfection of Bcl-2 
For stable transfection of MDA-MB-231, cells were transfected with pcDNA3 
Bcl-2 plasmid (Addgene plasmid 8768) using Fugene HD (Roche) and clonal selection 
was carried out using G418 (Sigma). Antibiotic concentration was gradually increased 
and resistant each single clone was seeded in 96-well plates. Selected clones were 
verified by qRT-PCR and immunoblotting analysis of Bcl-2 and maintained in growth 
medium with 700 µg/ml G418 [105]. 
3.2.13 Total Protein Isolation 
Each cell line was treated with appropriate drugs. First, all samples were washed 
with ice-cold 1 X PBS and lysed on ice in a solution containing 20 mM Tris-HCl (pH 
7.5), 150 mM NaCl, NP-40 0.5 %, (v/v), 1 mM EDTA, 0.5 mM PMSF, 1 mM DTT, 
protease inhibitor cocktail (Complete from Roche, Germany). After cell lysis cell debris 
was removed by centrifugation 15 min at 13200 rpm [104]. 
3.2.14 Determination of Protein Concentration 
Protein concentrations in nuclear and total protein extracts were determined by 
Bradford reagent (Biorad). Bovine serum albumin (BSA) was as the standart protein. 0, 
2, 4, 6, 8, 10 µl’s of 1 mg/ml BSA were taken which were corresponded to 0, 2, 4, 6, 8, 
10 µg/ml proteins, respectively. 1 µl of each unknown protein extract was completed to 
10 µl with distilled H2O. After then 290 µl (1:5) diluted Bradford reagent according to 
manufacturer instructions was added. All samples were kept at dark for 5 min. Protein 
concentrations were determined by spectrophotometrically at 595 nm absorbance. The 
standard curve was generated from A595 values of BSA protein standards (y-axis) versus 
protein amounts of BSA (x-axis). It is essential the curve is linear with correlation 
coefficient (R2 value). Protein concentrations of unknown samples were generated from 
standard curve graph. For every new assay, standard curve is repeated [107]. 
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3.2.15 Immunoblotting 
Total protein lysates (30 µg) were separated on a 12 % SDS-PAGE and 
transferred onto PVDF membranes. The membranes were then blocked with 5 % milk 
blocking solution in TBS-Tween-20 and incubated with appropriate primary and 
horseradish peroxidase (HRP)-conjugated secondary antibodies (Cell Signaling 
Technology) in antibody buffer containing 5 % (w/v) milk blocking solution. After 
washes with TBS-Tween-20, proteins were analyzed using an enhanced 
chemiluminescence detection system (ECL or ECL-Advance, Amersham Pharmacia 
Biotech) and exposed to Hyperfilm-ECL (Amersham Pharmacia Biotech). 
3.2.16 Detection of reactive oxygen species 
For assessment of ROS produced by different drugs in the cell cytotoxicity 
experiment, 2x105 cells were grown on 12 well plates and the 2’-7’ dichlorofluorescein 
(DCF) assay was used. Following drug treatment, MCF-7, MDA-MB-231, MCF-7 Bcl-2+  
and MDA-MB-231Bcl-2+ cells were washed with 1 X PBS and DCF-DA (5 µg/ml) in 
PBS was added into each well. After 30 min, PBS buffer containing excess DCF was 
removed from the cells and replaced with fresh PBS. Fluorescent intensity was 
measured at 485 nm excitation and 520 nm emission on a Spectramax Gemini 
Fluorometer plate reader [109]. Samples were also analyzed by flurosent microscopy 
(Olympus IX70) [109]. 
3.2.17 Detection of lipid peroxidation 
The extent of lipid peroxidation in control and drug exposed samples was 
determined by measuring the thiobarbituric acid reactive substance (TBARS). TBARS 
were determined according to the procedures of Okhawa et al. with minor modifications 
[110]. At the end of the experimental procedure, 2x105 cells were washed with 1 X PBS 
and scraped. After then, 10 % SDS was added for solubilization. This was followed by 
650 µl of 0.5 % thiobarbituric acid in 20 % (v/v) glacial acetic acid (pH 3.5) were 
added. All samples were incubated at 80°C for 30 min and cooled to room temperature 
before absorbance read at 532 nm spectophotometrically on microplate titer (Biorad). 
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3.2.18 Statistical analysis 
All samples were evaluated statistically using an Excel calculation file. MTT cell 
viability, M30 Apoptosense ELISA assay, caspase-9 activity and relative expression of 
mRNA was shown as Mean ± Standard Deviation, and the student’s t-test was applied 
to understand the probability efficiency. Differences were regarded as statistically 
significant at values of p < 0.05. 
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CHAPTER 4 
 
 
 
 
 
 
4 RESULTS 
4.1 Cisplatin and paclitaxel induces apoptosis 
MCF-7 (p53 wt) and MDA-MB-231 (p53 mt) breast cancer cells which are highly 
metastatic were studied to investigate whether cisplatin or paclitaxel decreased cell 
viability through the induction of apoptosis.  
To assess the cytotoxic effect of cisplatin or paclitaxel, MCF-7 and MDA-MB-
231 cells were treated with each agent at various concentrations for 24 h. Cell viability 
was determined by MTT Cell Proliferation Assay. Since moderate cytotoxic effects 
were observed at 30 µM cisplatin and 20 nM paclitaxel (30 % and 15 % decrease in cell 
viability in MCF-7 cells and 29 % and 23 % decrease in cell viability in MDA-MB-231 
cells, respectively) (Figure 4.1-2), these concentrations were determined to be used in 
further experiments. The higher concentrations of cisplatin and paclitaxel were found 
more than 50 % cytotoxic for both cell lines. 
During apoptosis, caspases cleave various cellular proteins. In epithelial cells, 
one of those substrates is the intermediate filament protein CK18. Cleavage of CK18 
results in collapse of the cytokeratin filaments into large aggregates. The M30 antibody 
detects a neo-epitope region which is exposed after cleavage of CK18 by caspases after 
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aspartic acid residue 396 (CK18Asp396). To confirm that the decrease in cell viability 
was indeed due to apoptosis, we performed the M30 Apoptosense ELISA Assay.  
 
Figure 4.1 The cytotoxic effect of cisplatin was determined by MTT cell viability 
assay following exposure of MCF-7 and MDA-MB-231 cells to cisplatin for 24 h. 
Columns represent the mean (±SEM) values obtained from at least two different 
assays (N=3), each comprising six replicates. *P < 0.05. 
 
Figure 4.2 The cytotoxic effect of paclitaxel was determined by MTT cell 
viability assay following exposure of MCF-7 and MDA-MB-231 cells to 
paclitaxel for 24 h. Columns represent the mean (±SEM) values obtained from at 
least two different assays (N=3), each comprising six replicates. *P < 0.05. 
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30 µM cisplatin increased M30 antigen levels by 2.5 fold and 1.9 fold in MCF-7 
and MDA-MB-231 cells, respectively (Figure 4.3). In addition, 20 nM paclitaxel 
increased M30 antigen levels by 1.6 and 2.0 fold compared to control sample in both 
cell line (drug vs control ** P <0.01).  
 
Figure 4.3 Apoptotic cell death was determined by M30 Apoptosense ELISA 
assay. MCF-7 and MDA-MB-231 breast cancer cells were grown up on 96 well 
plates and treated with 20 nM paclitaxel,30 µM cisplatin and 10 µM HA14-1 for 
24 h. Columns represent the mean (±SEM) values obtained from at least two 
different assays (N=2), each comprising four replicates. **P < 0.01. 
4.2 Bcl-2 siRNA enhances drug-induced apoptosis in breast cancer cells 
The efficiency of Bcl-2 siRNA on Bcl-2 protein levels was assessed at 24 h and 
48 h following transfection. Transfection of Bcl-2 siRNA markedly down-regulated 
Bcl-2 within 48 h. We did not detect any effect of scramble siRNA on Bcl-2 protein 
levels in both cell lines. As shown Figure 4.4 and 4.5, Bcl-2 siRNA transfection 
decreased Bcl-2 mRNA or protein levels. Transfection ratio was determined as 1:9 and 
1:6 for siRNA:transfection reagent complex in MCF-7 and MDA-MB-231 cells, 
respectively. The lower transfection ratios were not sufficient to down-regulate Bcl-2 
levels in both cell lines. 
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Figure 4.4 Relative mRNA copy numbers were determined by quantitative real 
time PCR assay following transfection of MCF-7 and MDA-MB-231 cells with 
Bcl-2 siRNA and scramble siRNA for 48 h. Bcl-2 mRNA copy number was 
calculated using standard curve of GAPDH. Represented values are normalized 
by dividing with GAPDH. Columns represent mean (±SEM) of independent two 
experiments (N=3), each comprising six replicates. 
 
Figure 4.5 Silencing of Bcl-2 by siRNA enhanced drug induced apoptosis. Bcl-2 
siRNA silencing effect and efficient transfection reagent complex ratio was 
determined by western blotting. NS is scramble siRNA. 
To investigate if treatment with Bcl-2 siRNA itself had any effect on cell 
viability, we performed the MTT cell viability assay after 48 h siRNA transfection. The 
results here (Figure 4.6) showed that Bcl-2 siRNA did not decrease cell viability. When 
transfection of Bcl-2 siRNA was followed by treatment with cisplatin, cell viability 
further reduced by 52 % and 57 % in MCF-7 and MDA-MB-231 cells, compared to 
treatment with scramble siRNA and cisplatin, respectively. Similarly, transfection of 
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Bcl-2 siRNA followed by treatment with paclitaxel, reduced cell viability by 43 % and 
65 % in both cell lines, compared to treatment with scramble siRNA and paclitaxel.  
 
Figure 4.6 Silencing of Bcl-2 by siRNA enhances cytotoxic effects of drugs. Cell 
viability was determined by MTT assay. After silencing procedure, MCF-7 and 
MDA-MB-231 breast cancer cells were treated with 30 µM cisplatin and 20 nM 
paclitaxel for 24 h. Columns represent the mean (±SEM) values obtained from at 
least two different assays (N=2), each comprising four replicates. *P < 0.05 
These findings were consistent with a possible increase in apoptosis and we 
performed M30 Apoptosense ELISA Assay. Down-regulation of Bcl-2 by siRNA 
resulted in increased apoptotic response by chemotherapeutic drugs. As demonstrated in 
Figure 4.7, each chemotherapeutic drug induced M30 antigen levels due to apoptotic 
cell death more than parental cells in the transiently Bcl-2 silenced cells (P <0.05). This 
finding indicates that transient silencing of Bcl-2 in both cells enhanced apoptotic 
effects of cisplatin and paclitaxel. 
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Figure 4.7 Silencing of Bcl-2 by transient siRNA treatment enhanced drug-
induced apoptosis. Apoptotic cell death was determined by M30 Apoptosense 
ELISA assay in MCF-7 and MDA-MB-231 cells. Columns represent the mean 
(±SEM) values fold increased compare to control obtained from at least two 
different assays (N=2), each comprising four replicates. *P < 0.05. 
4.3 The Bcl-2 antagonist, HA14-1, sensitizes breast cancer cells to drugs 
Since anti-apoptotic Bcl-2 family members likely contribute to resistance in 
cancer chemotherapy by raising the threshold for apoptosis, we investigated whether the 
addition of Bcl-2 inhibitor (HA14-1) would potentiate the apoptotic induction by 
chemotherapeutics. Initially we determined dose dependent effect of HA14-1 on MCF-7 
and MDA-MB-231 cells. Cells were exposed to various concentrations of HA14-1 for 
24 h (Figure 4.8) and cell viability was determined by MTT assay. 
HA14-1 between 1 to 5 µM concentrations for MCF-7 cells and between 1 to 8 
µM concentrations for MDA-MB-231 cells did not significantly decrease cell viability 
in both cell lines as compared to control (P> 0.05). Whereas HA14-1 (10 µM) reduced 
cell viability by 22 % and 15 % in MCF-7 and MDA-MB-231 cells, respectively (P 
<0.05 Figure 4.9). We found out that pre-treatment of HA14-1 (10 µM) markedly 
enhanced the cytotoxic effect of cisplatin or paclitaxel as compared to drug alone 
treatment in MCF-7 cells (Figure 4.9). 
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Figure 4.8 Determination of HA14-1-induced cytotoxic response. MCF-7 and 
MDA-MB-231 breast cancer cells were treated with HA14-1 for 24 h. The 
number of viable cells was determined by MTT assay. Columns represent the 
mean (±SEM) values obtained from at least two different assays (N=3), each 
comprising six replicates. * P < 0.05. 
 
However, HA14-1 (10 µM) pre-treatment followed by cisplatin significantly 
increased the cytotoxic effect of cisplatin by 41 % (*P <0.05, cisplatin vs HA14-1 plus 
cisplatin), 10 µM HA14-1 pre-treatment was less potent for the cytotoxic effect of 20 
nM paclitaxel in MDA-MB-231 cells (paclitaxel vs HA14-1 plus paclitaxel, *p>0.05) 
(Figure 4.10). 
These findings were also confirmed with M30 Apoptosense ELISA Assay which 
determines apoptotic cell populations. Pre-treatment of 10 µM HA14-1 followed by 30 
µM cisplatin increased M30 antigen concentration by 3.7 and 2.9 fold in MCF-7 and 
MDA-MB-231 cells as compare to cisplatin alone, respectively (P <0.05). However, 
pre-treatment of 10 µM HA14-1 followed by 20 nM paclitaxel treatment significantly 
increased apoptosis by 3.1 fold in MCF-7 cells (P <0.05), by contrast pre-treatment of 
10 µM HA14-1 followed by 20 nM paclitaxel treatment did not significantly increased 
M30 antigen levels as compared to paclitaxel alone in MDA-MB-231 cells (1.9 vs 2.0 
fold; P >0.05) (Figure 4.11). 
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Figure 4.9 Pre-treatment with HA14-1 enhances cisplatin-induced cytotoxic 
responses in MCF-7 (up) and MDA-MB-231 (down) cells. The number of viable 
cells was determined by MTT assay. Columns represent the mean (±SEM) values 
obtained from at least two different assays (N=3), each comprising six 
replicates.*P < 0.05. 
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Figure 4.10 Pre-treatment with HA14-1 enhances paclitaxel-induced cytotoxic 
responses in MCF-7 (up) and MDA-MB-231 (down) cells. The number of viable 
cells was determined by MTT assay. Columns represent the mean (±SEM) values 
obtained from at least two different assays (N=3), each comprising six 
replicates.*P < 0.05. 
In order to understand the effect of HA14-1 on Bcl-2 expression, we determined 
Bcl-2 protein levels following HA14-1 treatment. As shown in Figure 4.12 10 µM 
HA14-1 did not alter total amount of Bcl-2 at different time points within 24 h of 
treatment in both cell lines.  
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Figure 4.11 Pre-treatment of MCF-7 and MDA-MB-231 cells with HA14-1 
potentiates the drug-induced apoptosis. Apoptotic responses were determined by 
M30 Apoptosense ELISA assay. The concentration of M30 antigen is presented as 
Units per Liter (U/L). Columns represent the mean (±SEM) values obtained from 
at least two different assays (N=2), each comprising four replicates. *P < 0.05. 
 
Figure 4.12 MCF-7 and MDA-MB-231 cells were treated with 10 µM HA14-1 
for 24 h. Bcl-2 expression was determined by immunoblotting. β-actin was used 
as loading control. 
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4.4 Bcl-2 inhibitor potentiates drug-induced apoptosis 
To investigate whether drug-induced apoptosis is mediated by caspases, the 
proteolytic activation of caspase-9 was examined in both cell lines. As shown in Figure 
4.13 following drug treatment, caspase-9 activity was increased compare to control in 
MCF-7 and MDA-MB-231 cells, respectively. Pre-treatment of HA14-1 significantly 
increased drug-induced caspase-9 activity.  
Colorimetric caspase-9 activity results were also confirmed by immunoblotting in 
drug-insensitive MDA-MB-231 cells. Pre-treatment with HA14-1 followed by cisplatin 
or paclitaxel treatment induced cleavage of pro-caspase-9 in MDA-MB-231 cells 
(Figure 4.14).  
 
Figure 4.13 Determination of Caspase-9 activity. Colorimetric caspase-9 activity 
was determined by spectrophotometrically (Abs 415). Columns represent the 
mean (±SEM) values obtained from at least two different assays. Cis= Cisplatin, 
Pac= Paclitaxel. 
As shown in Figure 4.14, caspase-3 was cleaved after cisplatin treatment but 
paclitaxel and HA14-1 did not induce caspase-3 cleavage in MDA-MB-231 cells. In 
addition, pre-treatment of cells with HA14-1 followed by paclitaxel induced cleavage of 
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pro-caspase-3. Thus Bcl-2 inhibitor enhanced paclitaxel induced cleavage of pro-
caspase 3 to active form (p19/17) in MDA-MB-231 cells. 
Engagement of apoptosis is further confirmed by the detection of PARP 
degradation. HA14-1 increased the paclitaxel- and cisplatin-induced PARP cleavage as 
opposed to drug treatment-only cases in drug-insensitive MDA-MB-231 cells (Figure 
4.14).  
 
Figure 4.14 The cleavage of caspase-3, caspase-9 and PARP were determined in 
MDA-MB-231 cells. Thirty micrograms total protein lysate subjected to 12 % 
SDS-PAGE for western blot analysis with specific antibodies (anti-caspase-3, 
caspase-9 and PARP). β-actin was used as an internal loading control. CF= 
Cleaved fragment. 
In this study, pan-caspase inhibitor, (z-VAD-fmk), caspase-3 inhibitor (z-DEVD-
fmk) and caspase-9 inhibitor (z-LEHD-fmk) were used to address the significance of 
caspase activation. Drug-insensitive MDA-MB-231 cells were exposed to these 
inhibitors for 1 h. After this, cells were pre-treated with HA14-1 followed by cisplatin 
or treated with only cisplatin 24 h. Cytotoxicity was evaluated by MTT assay. 
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Treatment with caspase inhibitors, each at 20 µM concentration, prevented cytotoxic 
effects of cisplatin and HA14-1 plus cisplatin. These findings suggest that the 
synergistic effect of HA14-1 with cisplatin was caspase-dependent (Figure 4.15). 
 
Figure 4.15 Cisplatin induced apoptosis was caspase dependent. MDA-MB-231 
cells were pre-treated with HA14-1 followed by cisplatin or cisplatin alone after 
1h prior treatment pan-caspase general inhibitor, caspase-3 inhibitor and caspase-
9 inhibitor (each 20 µM) for 24 h. Cell viability was analyzed by MTT assay. 
Columns represent the mean (±SEM) values obtained from at least two different 
assays (N=2), each comprising four replicates. 
 
Figure 4.16 Determination of mitochondrial membrane potential (MMP) 
following drug treatment in MCF-7 cells. The loss of MMP was measured by 
rhodamine 123 staining and analyzed by fluoresence microscopy. Following 
treatment of MCF-7 cells with appropriate drugs for 24 h, rhodamine 123 (5 mM) 
was loaded for 30 min. Results were repeated twice and magnification was 100 X. 
Green fluorescence filter was used in fluorescence invert microscopy. 
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In order to determine drug-induced apoptotic events, MMP loss was examined 
following drug treatment in MCF-7 and MDA-MB-231 cells, respectively. To assess the 
MMP loss, cells were stained with rhodamine 123 dye which accumulates in living cells 
and binds to mitochondria membrane. As shown in Figure 4.16 and 4.17, cisplatin and 
paclitaxel treatment for 24 h increased loss of MMP in both cell lines. Pre-treatment of 
HA14-1 further increased the MMP loss in cisplatin treated cells in MCF-7 and MDA-
MB-231 cells, respectively. Although, prior treatment of HA14-1 followed by cisplatin 
further increased MMP loss in MDA-MB-231 cells, paclitaxel treatment did not show 
remarkable increase in loss of MMP. Of note, alone HA14-1 treatment did not decrease 
MMP in both cell lines compare to control. 
 
Figure 4.17 Determination of  mitochondrial membrane potential (MMP) 
following drug treatment in MDA-MB-231 cells. The loss of MMP was measured 
by rhodamine 123 staining and analyzed by fluoresence microscopy. Following 
treatment of MDA-MB-231 cells with appropriate drugs for 24 h, rhodamine 123 
(5 mM) was loaded for 30 min. Results were repeated twice and magnification 
was 200 X. Green fluorescence filter was used in fluorescence invert microscopy. 
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4.5 Modulation of Bcl-2 family members in drug-induced apoptosis 
Bcl-2 exerts a significant part of its survival function by physically interacting 
with pro-apoptotic members of the Bcl-2 family. In this study, to identify the role of 
Bcl-2 family members in drug-induced apoptosis, we investigated mRNA levels and 
protein levels of various Bcl-2 family members following drug treatment.  
Here we showed that cisplatin or paclitaxel did not significantly down-regulate 
Bcl-2 mRNA (P> 0.05 vs untreated control sample) and protein level in MCF-7 cells 
(Figure 4.18). Although cisplatin did not decrease Bcl-2 mRNA levels in MCF-7 cells, 
pre-treatment of this cells with HA14-1 slightly increased down-regulation of Bcl-2 
following cisplatin treatment (P> 0.05 vs drug treatment).  
According to immunoblotting results, pre-treatment of MDA-MB-231 cells with 
HA14-1 followed by cisplatin down-regulated Bcl-2 expression whereas this ratio was 
not significant following paclitaxel, HA14-1 and HA14-1 plus cisplatin treatment in 
MDA-MB-231 cells (Figure 4.20). Interestingly, pre-treatment of HA14-1 followed by 
cisplatin led to sharp decrease in Bcl-2 protein levels in MDA-MB-231 cells (Figure 
4.20). Pre-treatment of MCF-7 cells with HA14-1 followed by cisplatin treatment did 
not significantly alter Bcl-2 expression.  
We determined Bcl-xL mRNA and protein levels in MCF-7 and MDA-MB-231 
cells following drug treatment. Although pre-treatment of MCF-7 cells with HA14-1 
followed by cisplatin or paclitaxel treatment did not alter Bcl-2 expression, prior 
treatment of MCF-7 cells with Bcl-2 inhibitor followed by cisplatin or paclitaxel 
treatment significantly decreased Bcl-xL mRNA levels (P < 0.05 vs alone drug 
treatment and untreated control sample), Figure 4.18). Results were also confirmed by 
immunoblotting. 
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Cisplatin and paclitaxel treatment decreased Bcl-xL mRNA levels (P< 0.05 vs 
untreated control sample) and down-regulated Bcl-xL expression in MDA-MB-231 
cells. Pre-treatment of MDA-MB-231 with HA14-1 also down-regulated Bcl-xL protein 
levels, even more drastically than cisplatin or paclitaxel treated MDA-MB-231 cells. Of 
note, treatment with HA14-1 led to a decrease in Bcl-xL mRNA levels similar to 
treatment with cisplatin and paclitaxel in both cell lines in MDA-MB-231 cells. 
 
Figure 4.18 Modulation Bcl-2 family members in drug exposed MCF-7 cells. 
MCF-7 cells were pre-treated with HA14-1 followed by cisplatin or paclitaxel, 
cisplatin alone, paclitaxel alone and HA14-1 alone for 24 h. Bcl-2, Bax, Bcl-xL 
and Puma copy numbers were calculated using standard curve of 18s RNA. These 
values are normalized by dividing with 18s RNA. Columns represented Mean ± 
S.D and representative of independent two experiments (N=2), and each 
experiment was repeated three times. 
In order to understand the modulation of pro-apoptotic Bcl-2 family members in 
drug-induced apoptosis, we first determined Bax mRNA and protein levels following 
drug-treatment in the presence or absence Bcl-2 inhibitor. According to quantitative 
PCR results, cisplatin, paclitaxel and HA14-1 increased Bax mRNA level in MCF-7 and 
MDA-MB-231 cells, respectively (P< 0.05 vs untreated control sample). However, pre-
treatment of MCF-7 cells with HA14-1 followed by cisplatin or paclitaxel did not 
increase Bax mRNA levels (P> 0.05 vs drug treatment). We established that pre-treatment 
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of MDA-MB-231 cells with HA14-1 followed by cisplatin increased Bax mRNA levels 
but paclitaxel did not exert same effect compare to alone paclitaxel treatment in MDA-
MB-231 cells. According to immunoblotting results, pre-treatment of MDA-MB-231 
cells with Bcl-2 inhibitor increased cisplatin and paclitaxel induced Bax protein levels 
(Figure 4.20). 
 
Figure 4.19 Modulation Bcl-2 family members in drug exposed MDA-MB-231 
cells. a. MDA-MB-231 breast cancer cells were pre-treated with HA14-1 followed 
by cisplatin or paclitaxel, cisplatin alone, paclitaxel alone and HA14-1 alone for 
24 h. Bcl-2, Bax, Bcl-xL and Puma copy numbers were calculated using standard 
curve of β-actin. These values are normalized by dividing with β-actin. The data 
were represented Mean ± S.D and representative of independent two experiments 
(N=3), and each experiment was repeated three times. 
To assess the role of Puma in drug-induced apoptosis mechanism we determined 
Puma mRNA and protein levels following drug treatment in MCF-7 and MDA-MB-231 
cells, respectively. As shown in Figure 4.18 and 4.19, although cisplatin and HA14-1 
treatment up-regulated Puma expression in both cell lines, paclitaxel did not exert same 
effect in MDA-MB-231 cells. Pre-treatment of MCF-7 and MDA-MB-231 cells with 
HA14-1 followed by cisplatin and paclitaxel further increased Puma expression (P< 
0.05 vs drug treatment). 
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In order to reveal the role of other pro-apoptotic Bcl-2 family protein, Bad in 
drug-induced apoptosis mechanism, we determined Bad expression following drug 
treatment in MCF-7 and MDA-MB-231 cells, respectively. Cisplatin and paclitaxel 
treatment increased Bad expression in MCF-7 and MDA-MB-231 cells. Although 
HA14-1 treatment increased Bad expression in MCF-7 cells, we did not observe any 
change in Bad expression profile in MDA-MB-231 cells following HA14-1 treatment. 
Pre-treatment of MDA-MB-231 cells with HA14-1 followed by cisplatin significantly 
increased Bad expression but, pre-treatment HA14-1 did not potentiate the paclitaxel 
induced Bad expression in the same cell line (Figure 4.20). 
 
Figure 4.20 Modulation Bcl-2 family members following drug treatment of MCF-
7 and MDA-MB-231 cells. Thirty micrograms total protein lysate were subjected 
to western blots with antibodies directed against the Bcl-2 family members. β-
actin was used as loading control. Pac= Paclitaxel, Cis= Cisplatin, HAP= HA14-
1+paclitaxel, HAC=HA14-1+cisplatin. 
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4.6 Prevention of cytotoxic effects of drugs in Bcl-2 overexpressing breast cancer 
cells 
To establish the role of Bcl-2 overexpression in drug induced apoptosis, we set up 
stable Bcl-2 overexpressing MDA-MB-231 cells following G418 selection. Bcl-2 
overexpression was determined by qRT-PCR (Figure 4.21). We also checked relative 
Bcl-2 mRNA copy number in MCF-7 Bcl-2 overexpressing cells which was provided 
by Dr. Ozgur Kutuk. 
 
Figure 4.21 Determination of Bcl-2 overexpression in stable transfected MCF-7 
and MDA-MB-231 cells. Each sample (700 ng cDNA) was amplified for Bcl-2 
with qRT-PCR. Columns represents the mean value of two different experiments. 
β-actin was used as house-keeping gene and fold increase in Bcl-2 mRNA was 
calculated according to β-actin standart curve. PCR efficiency was determined as 
at least 85 %. 
In order to establish Bcl-2 overexpressing stable cell line, MDA-MB-231 cells 
were transfected with Bcl-2 plasmid. Following G418 antibiotic treatment for clone 
selection, resistant clones were picked up under microscopy and seeded in 96 wells. 
Each clone was isolated for their RNA and investigated for Bcl-2 overexpression ratio 
(Figure 4.22).  
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Figure 4.22 MDA-MB-231 cells were transfected with Bcl-2 plasmid and 
selected with G418 (700 µg/ml). Selected clones were verified by western 
blotting. From left side to right site clone 1, 2 and 3. Clone 3 was used in further 
experiments. 
Since Bcl-2 is known to protect against various apoptotic insult including 
chemotherapeutic drugs, we evaluated how Bcl-2 overexpression alters apoptotic 
response induced by two drugs with different mechanism of action; a microtubule 
damaging taxane (paclitaxel) and a DNA-damaging platinum agent (cisplatin). First we 
determined cell viability following each drug treatment. As shown in Figure 4.23, 
cisplatin decreased cell viability by 50 % after 72 h of treatment in MCF-7 Bcl-2+ 
(P<0.05 vs control), whereas this ratio was 21 % in MDA-MB-231Bcl-2+. While pre-
treatment of HA14-1 enhanced the cytotoxic effect of cisplatin in MCF-7 Bcl-2+ cells 
(cell viability decrease by 75 %), pre-treatment of HA14-1 failed to exert additional 
cytotoxic effect (cell viability decrease by 27 %) when combined with cisplatin 
treatment in MDA-MB-231Bcl-2+ (drug vs combined treatment p>0.05).  
Although paclitaxel, cisplatin or HA14-1 treatment for 24 h significantly induced 
apoptosis in MCF-7 and MDA-MB-231 cells, overexpression of Bcl-2 protected against 
apoptosis triggered by paclitaxel, cisplatin or HA14-1 following treatment for 24 h in 
both MCF-7Bcl-2+ and MDA-MB-231Bcl-2+ cells, respectively. This protective potency of 
Bcl-2 was still observed following paclitaxel and HA14-1 treatment for 48 h in Bcl-2 
overexpressing MCF-7 and MDA-MB-231 cells (Figure 4.23 and 4.24). Although Bcl-2 
overexpression abrogated paclitaxel- and HA14-1-induced apoptosis following 48 h 
treatment in MCF-7Bcl-2+ cells, cisplatin was able to trigger apoptosis. 
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Figure 4.23 The determination of cell viability in MCF-7Bcl-2+ breast cancer cells. 
MCF-7 Bcl-2+ breast cancer cells were treated with cisplatin, paclitaxel and HA14-
1 for 72 h and cell viability was evaluated by MTT assay. Columns represents the 
mean value of two different experiments (N=2). 
 
Figure 4.24 The determination of cell viability in MDA-MB-231Bcl-2+ breast 
cancer cells. MDA-MB-231 Bcl-2+ breast cancer cells were pre-treated with HA14-
1 followed by cisplatin for 72 h. 
Pre-treatment of Bcl-2 overexpressing MDA-MB-231 cells with HA14-1 did not 
lead to significant increase in cisplatin induced apoptosis within 72 h (P > 0.05, Figure 
4.23 and 4.24). According to this result, it can be concluded that MDA-MB-231 cells 
were more resistant to cisplatin than MCF-7 cells.  
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4.7 Modulating sensitivity to drug-induced apoptosis: Bcl-2 family members 
To evaluate the role of Bcl-2 expression levels in drug-induced apoptosis, we 
extracted protein samples from MCF-7Bcl-2+ cells following drug treatment (Figure 
4.25). In this experiment, MCF-7Bcl-2+ cells were specially chosen because cisplatin 
could overcome the Bcl-2 protection effect within 48 h. However, MDA-MB-231Bcl-2+ 
cells were found resistant to cisplatin within 48 h. According to immunoblotting results, 
cisplatin following 72 h treatment decreased total amount of Bcl-xL and neither cisplatin 
nor paclitaxel changed the Bax expression level in Bcl-2 overexpressing MCF-7 cells.  
 
Figure 4.25 Modulation of Bcl-2 family members following drug treatment in 
MCF-7Bcl-2+ cells. β-actin was used as loading control. M=Mock is control 
plasmid. 
Puma and Noxa expression levels were determined in MCF-7Bcl-2+ cells. MCF-
7Bcl-2+ cells were treated with cisplatin for 72 h time interval. Following total RNA 
isolation, results were analyzed by qRT-PCR. As shown Figure 4.26 and 4.27, qRT-
PCR analysis demonstrated that Puma and Noxa transcription was induced following 
cisplatin treatment in MCF-7Bcl-2+ within 48 h (P< 0.05 vs control).  
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Figure 4.26 MCF-7Bcl-2+ breast cancer cells were treated with 30 µM cisplatin for 
0 to 72 h. Puma copy numbers were calculated using standard curve of 18s RNA. 
These values are normalized by dividing with 18s RNA. The data were 
represented Mean ± S.D and representative of (N=2) with three replicates. 
 
 
Figure 4.27 MCF-7Bcl-2+ breast cancer cells were treated with 30 µM cisplatin for 
0 to 72 h. Noxa copy numbers were calculated using standard curve of 18s RNA. 
These values are normalized by dividing with 18s RNA. The data were 
represented Mean ± S.D and representative of independent two experiments 
(N=2) with three replicates. 
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4.8 The role of Bcl-2 expression in drug-induced ROS production and lipid 
peroxidation 
In order to understand the role of Bcl-2 in ROS generation and lipid peroxidation 
in drug-induced apoptosis mechanism, we first examined MCF-7 cells which were more 
sensitive to cisplatin than MDA-MB-231 cells. While cisplatin alone induced generation 
of DCF-DA signal, Bcl-2 depletion considerably enhanced this response (Figure 4.28). 
 
Figure 4.28 The determination of ROS generation in MCF-7 breast cancer cells 
which were treated with 20 nM paclitaxel, 30 µM cisplatin, 10 µM HA14-1 and 
Bcl-2 siRNA for 24h. Columns represent the mean (±SEM) values obtained from 
at least two different assays (N=3), each comprising six replicates. Excitation 
488nm, emission 515nm. 
Cisplatin, Paclitaxel, HA14-1 or Bcl-2 siRNA treatment increased ROS 
generation in MCF-7 cells. Pre-treatment of MCF-7 cells with HA14-1 significantly 
increased cisplatin induced ROS generation whereas pre-treatment of HA14-1 did not 
increase paclitaxel-induced ROS generation (P> 0.05 combined treatment vs paclitaxel 
treatment, Figure 4.29). 
79 
 
 
Figure 4.29 The determination of ROS generation in MCF-7 breast cancer cells 
which were treated with 20 nM paclitaxel, 30 µM cisplatin, 10 µM HA14-1 for 
24h. Columns represent the mean (±SEM) values obtained from at least two 
different assays (N=3), each comprising six replicates. Excitation 488nm, 
emission 515nm. HAP= HA14-1 plus paclitaxel, HAC= HA14-1 plus cisplatin. 
Bcl-2 silencing in MCF-7 cells increased lipid peroxidation compare to parental 
MCF-7 cells (Figure 4.30). This finding was confirmed by Bcl-2 inhibitor, HA14-1 in 
MCF-7 cells (Figure 4.31). Here, we showed that pre-treatment of MCF-7 cells with 
HA14-1 followed by paclitaxel increased lipid peroxidation more than paclitaxel 
treatment. 
80 
 
 
Figure 4.30 The determination of TBARS levels in Bcl-2 silenced MCF-7 cells. 
NS is non silencing control. Columns represent the mean (±SEM) values obtained 
from at least two different assays (N=2), each comprising four replicates. 
 
Figure 4.31 TBARS levels were determined for MCF-7 breast cancer cells. The 
determination of TBARS amount in MCF-7 breast cancer cells which were 
exposed to 20nM paclitaxel, 30µM cisplatin in presence or absence of 10µM 
HA14-1 for 24h. Columns represent the mean (±SEM) values obtained from at 
least two different assays (N=2), each comprising four replicates. HAP= HA14-1 
plus paclitaxel, HAC= HA14-1 plus cisplatin. 
To investigate if ROS production was critical for cisplatin-induced apoptosis in 
MCF-7Bcl-2+ cells, we then similarly monitored the formation of intracellular ROS 
formation in these cells. Exposure of MCF-7Bcl-2+ to cisplatin for 24 h or 48 h did not 
trigger any increase in DCF-DA reactive ROS production compare to untreated control 
cells (Figure 4.32).  
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As shown in Figure 4.33, cisplatin treatment for 48 h induced lipid peroxidation 
as determined by elevated levels of TBARS in MCF-7Bcl-2+  cells, but cisplatin treatment 
for 24 h did not increase lipid peroxidation. Here we conclude that, cisplatin gradually 
decreased Bcl-2 expression and induced ROS production and lipid peroxidation, albeit 
with different time-dependent effectiveness.  
 
Figure 4.32 The determination of ROS generation in MCF-7Bcl-2+ breast cancer 
cells which were treated with 20 nM paclitaxel, 30 µM cisplatin, 10 µM HA14-1 
for 24h. Columns represent the mean (±SEM) values obtained from at least two 
different assays (N=3), each comprising six replicates. Excitation 488nm, 
emission 515nm. Cis= Cisplatin, Pac= Paclitaxel. 
 
Figure 4.33 The determination of TBARS amount in MCF-7Bcl-2+ breast cancer 
cells which were exposed to 30µM cisplatin, 20nM paclitaxel and 10µM HA14-1 
within72 h time interval. Columns represent the mean (±SEM) values obtained 
from three independent experiments (N=3). 
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Drug induced ROS production was also examined in drug-insensitive MDA-MB-
231 cells (Figure 4.34). Cisplatin treatment significantly increased ROS generation in 
MDA-MB-231 cells whereas paclitaxel was shown to be less potent to increase ROS 
generation. HA14-1 treatment did not increase ROS generation but pre-treatment of 
MDA-MB-231 cells with HA14-1 followed by cisplatin significantly increased ROS 
generation. Additional N-acetyl cystein (NAC), superoxide scavenger co-treatment with 
drugs prevented drug-induced ROS generation in MDA-MB-231 cells (Figure 4.34).  
 
Figure 4.34 The determination of ROS generation in MDA-MB-231 breast cancer 
cells which were treated with drugs in the presence or absence of N-acetyl cystein 
(5 µM) for 24 h. Columns represent Mean ± S.D and representative of 
independent two experiments (N=2) with four replicates. Pac= Paclitaxel, Cis= 
Cisplatin, HAP= HA14-1+paclitaxel, HAC= HA14-1+cisplatin. 
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5 DISCUSSION 
Resistance to anticancer therapy is a major obstacle both in clinical and molecular 
oncology. Several studies established that the overexpression of anti-apoptotic Bcl-2 
family proteins confers resistance to apoptosis and decrease the efficiency of 
therapeutics in various cancer types [58]. Despite the ongoing controversy on their 
prognostic role in breast cancer [111] Bcl-2 and Bcl-xL reported to be overexpressed in 
majority (70 %) of breast cancer cases. In experimental breast cancer model systems, 
the overexpression of anti-apoptotic Bcl-2 family members causes increased resistance 
to drug-induced apoptosis and lead to enhanced angiogenesis and metastatic potential 
[111]. Accordingly the inhibition of anti-apoptotic Bcl-2 family proteins potently 
inhibits tumor growth and induces apoptosis or augments the action of conventional 
cytotoxics both in vivo and in vitro. Thus Bcl-2 and Bcl-xL seem to be very promising 
targets for therapeutic intervention [111]. 
Solid tumors are difficult to treat, though surgery is performed where it is 
possible, chemotherapy is mostly the choice of treatment. One of the major limitations 
of chemotherapy is the inability of anti-cancer agents to induce cytotoxicity due to 
inaccessibility of certain cells in a tumor. Moreover the histopathological heterogeneity 
in human tumors is a well-documented phenomenon. It is now widely admitted that 
breast carcinoma is a genetically and clinically heterogeneous disease as it contains 
different clones of tumor cells arising from the continual differentiation of transformed 
progenitor cells [112].  
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In this study, we determined that cisplatin and paclitaxel display distinct modes of 
action to induce apoptosis in MCF-7 and MDA-MB-231 cells which represents two 
different types of breast cancer cells. MCF-7 cells are low-migrating cells which are 
expressing ER  while MDA-MB-231 cells are lack of ER  with high mobility and 
invasive potential. Both of them are referred as highly metastatic. According to MTT 
cell viability assays 30 µM cisplatin and 20 nM paclitaxel were moderately cytotoxic 
and induced apoptosis in MCF-7 and MDA-MB-231 cells, respectively. The higher 
concentrations of each drug were found more than 50 % cytotoxic. These concentrations 
were used for further experiments to evaluate the role of Bcl-2 in drug-induced 
apoptosis mechanism (Figure 4.1-4.3). It should be highlighted that the optimal dosing 
of chemotherapeutic agents is critical not only suppression of tumor growth but also to 
minimize their cytotoxicity in normal cells. Previous reports pointed out that high 
plasma concentration of several drugs was shown to cause several toxicity to normal 
tissues, including heart [113]. Thus, optimization of the treatment concentration is very 
important to build a study model to understand the molecular basis of chemoresistance 
mechanism. 
In recent years gene therapy tools gained importance in order to overcome the 
non-specific effects of drugs and resistance problem. Antisense compounds are valuable 
agents to explore the function of gene products as they enable the through specific 
down-regulation of gene expression, providing opportunity to evaluate the 
consequences of that down-regulation on physiological events. Among their current 
applications, antisense molecules also have potential for use as anticancer therapeutics. 
Single stranded oligonucleotides or siRNAs are in development as agents to specifically 
modulate processes on which tumor cells depend for viability and growth. They can 
have reduced non-specific toxicity and improved anti-tumor activity compared with to 
the traditional cancer drugs. Several of these drugs (including Bcl-2, survivin, XIAP, 
and clusterin) are under investigation in phase I/II clinical trials [114]. 
Combination of novel therapeutic models with standard chemotherapeutic agents 
or radiotherapy was shown to have different effects according to cell characteristics and 
origin of tissue type. However limitations of gene therapy are still waiting for more 
progress in this area. A new phenomenon, RNAi is very useful technique to control 
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gene expression. It provides an additional shut-down mechanism for targeted genes. 
Therefore, stable or transient transfection of siRNAs which target different kinds of Bcl-
2 family members provides a detailed understanding to the overcome chemoresistance 
problem. Previous reports showed that Bcl-2 silencing approach appears to be a suitable 
strategy for sensitizing many kinds of cancer cells to various chemotherapeutics 
whereas their combined action was found drug and cell type specific [114, 115]. In our 
study, cisplatin and paclitaxel-induced apoptosis was promoted by Bcl-2 silencing 
approach in MCF-7 and MDA-MB-231 cells more than parental cells (Figure 4.6 and 
4.7). Therefore we conclude that Bcl-2 is an attractive target for novel treatment 
strategies of breast carcinoma. In aggrement with our results, Bcl-2 siRNA augmented 
cisplatin and paclitaxel induced apoptosis in glioblastoma cells and lung cancer cells, 
respectively [116]. 
Since pro-apoptotic Bcl-2 family proteins dock into the BH1-BH2 groove of anti-
apoptotic members via their BH3-domain, it has been proposed that BH3-mimetics can 
antagonize the anti-apoptotic members. Currently, a favored strategy for Bcl-2 
antagonism is based on small molecules targeting the Bcl-2 anti-apoptotic proteins by 
mimicking a BH3-domain [61]. Several compounds have been isolated or chemically 
synthesized, showing different binding specificity and affinity for BH3-domains of Bcl-
2 proteins and promoting apoptosis [84, 108, 117]. Among them is HA14-1 which leads 
to changes in Ca2+ homeostasis, inhibition of mitochondrial potential, Bax translocation, 
ROS generation, Cyt c release and caspase-9/-3 activation, and subsequently PARP 
cleavage [82, 89, 117-119]. The therapeutic effect of HA14-1 has been described in a 
variety of tumor cells. HA14-1 cooperates with other drugs such as flavopiridol, 
bortezomib, dexamethasone, doxorubicin and cytrabine [91, 119, 120]. Additionally, 
HA14-1 could potentiate non-toxic MAPK inhibitors as lethal agents in the cell culture 
environment [93]. Similar to HA14-1, ABT-263, AT-101, GX15-070, gossypol or 
oblimersen sodium (Genta) was also shown as apoptosis inducers as single agent. The 
success of HA14-1 or other BH3-mimicking drugs in combined or sequential therapy 
was shown to be cell and drug type dependent [121]. Interestingly gossypol is a natural 
product which was previously used for male contraception can induce apoptosis in 
Bax/Bak double deficient cells through changing conformation of Bcl-2 [122]. Similar 
to gosspol, chelerythrine can induce apoptosis through Bax/Bak independent 
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mitochondrial mechanism. This finding is very important to manage chemoresistance 
mechanism in Bax/Bak mutant cells which give less response to chemotherapeutics. 
In our study, pre-treatment of MCF-7 cells with HA14-1 (10 µM) significantly 
potentiated the cytotoxic effect of cisplatin and paclitaxel (P< 0.05 vs untreated 
sample). A previous study of hematopoetic cell lines found out that HA14-1 at 
concentrations higher than 25 µM led to a loss of selectivity for Bcl-2 and marked 
cytotoxicity in all cell lines tested [119]. In MDA-MB 231 cells, although pre-treatment 
of HA14-1 potentiated effect of cisplatin significantly, sensitization was much less 
when cisplatin was replaced by paclitaxel (Figure 4.9, P <0.05; Figure 4.10 P >0.05). 
These results were further confirmed by M30 Apoptosense ELISA assay which 
determines the caspase-induced CK18 cleavage in apoptotic cell populations (Figure 
4.11). Additionally, Bcl-2 protein level was checked but not found to be altered by to 
the treatment of HA14-1 (Figure 4.12).  
In order to understand the role of caspases in drug-induced apoptosis, we 
determined caspase-9 activity following cisplatin and paclitaxel treatment in MCF-7 
and MDA-MB-231 cells. Pro-caspase-3 cleavage was only detected in MDA-MB-231 
cells. Caspase-9 activity was significantly increased following cisplatin and paclitaxel 
treatment in MCF-7 and MDA-MB-231 cells, respectively (P< 0.05 vs untreated control 
sample, Figure 4.13). Inhibition of Bcl-2 enhanced the caspase-9 activation following 
cisplatin and paclitaxel treatment in both cell lines. Although cisplatin-induced caspase-
3 cleavage, paclitaxel did not exert same effect in MDA-MB-231 cells (Figure 4.14). 
According to this finding, paclitaxel-induced caspase-3 cleavage might be independent 
from the caspase-9 activation. It is also possible that paclitaxel acts via activation of 
another effector caspase, like caspases-6 or -7, or by an independent pathway. 
Previously, the possible involvement of caspase-7 in paclitaxel-induced apoptosis has 
been suggested in human esophageal squamous cancer cells and in non-small-cell lung 
cancer H460 and H520 cell lines [123]. Similar to our results, it was shown that HA14-1 
alone itself increased the caspase-3 and caspase-9 activation in cancer cells [89]. In 
addition, further increased caspase activity was determined following combined 
treatment of HA14-1 with cytotoxic agents and photo/radiation therapy models [89, 
124]. We also determined that cytotoxic effects of cisplatin or pre-treatment of MDA-
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MB-231 cells with HA14-1 followed by cisplatin treatment were prevented by pan-
caspase, caspase-9 and caspase-3 inhibitors (Figure 4.15). Thus, we conclude that 
cisplatin-induced apoptosis occurs by caspase dependent pathway. Consistent with our 
findings, pan-caspase, caspase-9 and caspase-3 inhibitors prevented HA14-1-induced 
apoptosis in follicular lymphoma B cells [125]. Similar to these findings, it was 
established that pre-treatment of z-VAD-FMK and α-tocopherol prevented the 
potentiating effect of HA14-1 with γ-radiation application in prostate cancer cells [89]. 
Under the light of these findings, we can conclude that inhibition or down-regulation of 
Bcl-2 was accompanied with drug-induced apoptosis mechanism and increased caspase 
activation. In order to understand the differential sensitizing effects of HA14-1 pre-
treatment followed by paclitaxel in MDA-MB-231 cells, further studies should focus on 
other effector caspases, or caspase independent cell death mechanisms. Additionally we 
found out that cisplatin and paclitaxel induced PARP cleavage in MDA-MB-231 cells 
(Figure 4.14). These findings indicate that cisplatin and paclitaxel induced 
mitochondrial apoptotic pathway in MCF-7 and MDA-MB-231 cells, respectively. The 
early loss of the MMP is a hallmark of apoptosis [126]. To assess the MMP loss, MCF-
7 and MDA-MB-231 were stained with rhodamine 123 fluorogenic probe following the 
drug treatment. In this study we determined that pre-treatment of HA14-1 further 
increased drug-induced MMP loss in MCF-7 and MDA-MB-231 breast cancer cells, 
respectively (Figure 4.16-4.17). Although caspase-9 activation was observed following 
HA14-1 treatment, HA14-1 did not significantly trigger MMP loss by itself. Similar to 
these results, HA14-1 was shown to induce MMP loss in murine leukemia cells and 
promote rapid loss of MMP following photodynamic therapy [118]. 
Balance between pro-apoptotic and anti-apoptotic members of Bcl-2 family 
determines the cell fate. Here the key question is how these proteins are recruited in 
response to toxic stimuli. As mentioned before, their expression levels have been 
implicated as major regulators in the control of mitochondrial apoptotic pathway. We 
presented here, HA14-1 pre-treatment followed by cisplatin or paclitaxel abrogated Bcl-
2 and Bcl-xL expression especially in MDA-MB-231 cells, albeit greater extends with 
cisplatin (Figure 4.19-4.20). HA14-1 drastically down-regulated Bcl-xL expression in 
MDA-MB-231 cells (Figure 4.20) however no significant down-regulation was 
observed for anti-apoptotic Bcl-2 family protein, Mcl-1. Given that other Bcl-2 
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inhibitors ABT-763 and GX14-070 (obatoclax) have shown to overcome Mcl-1-
mediated resistance, HA14-1 can be a less likely candidate to be used in treatment of 
Mcl-1 overexpressing cancers [83, 84].  
Although the pre-treatment of HA14-1 significantly increased paclitaxel or 
cisplatin induced cell death in MCF-7 cells, HA14-1 pre-treated MDA-MB-231 cells 
were more resistant to paclitaxel. Hence, modulation of pro-apoptotic and anti-apoptotic 
Bcl-2 family members might be an important key answer to understand the sensitizing 
effect of HA14-1 in various breast cancer cells. Recent reports suggested that 
phosphorylation of Bcl-2 is an important regulatory mechanism for its function and is a 
common event in response to anti-mitotic drugs [16]. In addition it was proposed that 
this post-translational modification may be necessary for Bcl-2's full and potent anti-
apoptotic function. Paclitaxel treatment activates members of the JNK/SAPK MAPK 
family, which then disable Bcl-2 through phosphorylation within its flexible loop region 
[16, 18]. Although paclitaxel can also bind to the loop of Bcl-2 protein, its significance 
is unclear. It is possible that mutations in the loop region of Bcl-2 could account for 
some cases of paclitaxel-resistance in contrast other mitotic blockers does not show this 
resistance suggesting that their recognition site on Bcl-2 protein is different [19]. 
However, it was pointed out that while paclitaxel induced Bcl-2 phosphorylation, it 
could also up-regulate Bax expression [127]. Thereby, other anti-apoptotic genes such 
as Bcl-xL should be considered in paclitaxel resistance cases. Further investigation of 
paclitaxel induced Bcl-2 phosphorylation and related up-stream events might be 
informative [18].  
A number of studies have indicated that cisplatin induces apoptosis via DNA 
damage responsive pathways which may vary depending upon cell type and molecular 
context. These pathways include p53 activation lead to transcriptional upregulation of 
pro-apoptotic members of the Bcl-2 family. Transcriptional regulation of Bcl-2 or Bcl-
xL in response to cisplatin has not generally been examined since suppression of anti-
apoptotic molecules has not been considered a transcriptional target of these DNA 
damage induced pathways [128]. Here, we showed that both HA14-1 or cisplatin 
treatment did not decrease Bcl-2 expression in MCF-7 and MDA-MB-231 cells, pre-
treatment of HA14-1 followed by cisplatin built a synergistic effect and further decrease 
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Bcl-2 expression (Figure 4.18-20). Identification of up-stream signaling events may 
clarify how this synergistic effect of both drugs decreases Bcl-2 mRNA and protein 
levels. Previous reports showed that H2O2 mediates Bcl-2 down-regulation by cisplatin 
through its ability to dephosphorylate the protein, which facilitates its ubiquitination and 
subsequent degradation by the proteasome [103]. Multiple pro-survival Bcl-2 family 
members are degraded by the ubiquitin-proteasome system; the best examples are the 
pro-survival members Bcl-2 and Mcl-1 [129] [130].Here we showed that cisplatin 
induced generation of ROS and this event may degrade Bcl-2 protein levels by 
ubiquitin-dependent proteolytic pathway. This event may trigger ubiquitin-dependent 
proteolytic control of transcriptional regulation of anti-apoptotic Bcl-2 family members. 
In further studies, proteosomal control of gene transcription and additional translational 
control of anti-apoptotic genes should be discussed to clarify drug-induced apoptosis 
and chemoresistance mechanism. 
Previous studies pointed out that, lack of Bax might cause a failure in response to 
HA14-1 [131]. Hence, determination of the Bax expression and related events in HA14-
1-exposed cell lines might be significant in the characterization of drug specific 
sensitizing effect of HA14-1. We herein demonstrated that Bax was markedly up-
regulated by the pre-treatment of HA14-1 followed by cisplatin or paclitaxel in MCF-7 
and MDA-MB-231 cells, respectively (Figure 4.19-4.20). Previous studies indicated 
that Bax undergoes conformational changes resulting in Bax homodimerization and 
mitochondrial membrane insertion in response to death signals from cytotoxic insults, 
such as survival factor withdrawal [132]. Although pre-treatment of HA14-1 followed 
by cisplatin induced Bax translocation paclitaxel did not significantly exert same effect 
in MDA-MB-231 cells [133]. Pre-treatment of HA14-1 did not increase Bax expression 
levels following cisplatin and paclitaxel treatment in MCF-7 and MDA-MB-231 cells. 
Considering the finding that cisplatin induced apoptosis in both parental MCF-7 
(p53 wild-type) and MDA-MB-231 (p53 mutated) cell lines, we can conclude that 
apoptosis induction by cisplatin does not require p53 transcriptional activity in parental 
breast cancer cells consistent with previous reports. However, the expression of Bcl-2 
and Bax appear to be regulated by the wild type form of p53 tumor suppressor gene. 
The Bcl-2 gene contains a p53-dependent negative response element through which p53 
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may, either directly or indirectly, transcriptionally downregulate the expression of Bcl-2 
[134]. The Bax gene promoter contains binding site sequences for p53 [135]. It was 
suggested that only wild type p53, not mutant, could transactivate the Bax gene 
promoter [60]. Similar to Bax, Puma, a BH3-only protein, is also a transcriptional target 
of p53-mediated apoptosis signaling. However, these genes could also be induced by 
p53-independent pathways Thus, p53 family members are important mediators of 
apoptosis and can be induced by a number of chemotherapeutics and radiation [136]. 
Puma acts by modulating Bax activity through binding to Bcl-xL and dissociate the 
interaction of Bax and Bcl-xL to facilitate Cyt c release from the mitochondria, thereby 
triggering the apoptotic cascade [137]. It was previously demonstrated that p53-
independent Puma up-regulation might be playing role in cisplatin-induced apoptosis in 
colon cancer cells [138]. Over-expression of Puma induces disorganization/disruption 
of the cellular microtubule network in apoptotic fibroblasts [138]. Therefore, 
microtubules displayed de-polymerized and dispersed structures throughout the 
cytoplasm. In contrast to the mechanistic action of Puma, paclitaxel and docetaxel 
induce the stabilization of microtubule formation and lead to a subsequent cell death. As 
shown in Figure 4.19, while cisplatin (30 µM) and HA14-1 (10 µM) were up-regulating 
Puma mRNA and protein expression, paclitaxel (20 nM) did not change up-regulate 
Puma expression in MDA-MB-231 cells. Based on these results, we conclude that 
cisplatin and HA14-1 induce p53-independent Puma up-regulation in MDA-MB-231 
cells, whereas paclitaxel failed to show any effect on Puma expression levels.  
Bad expression level was increased following cisplatin treatment more than 
paclitaxel treatment in MCF-7 and MDA-MB-231 cells, respectively. Previous reports 
showed that p53 transactivates Bad transcription and forms a Bad/p53 complex which 
induce mitochondrial apoptosis in lung cancer cells [139]. However, Bad plays dual 
roles in p53 transcriptional-dependent and -independent pathways. Upon treatment with 
a DNA damaging agent such as etoposide, upregulated p53 directly binds to the 
upstream promoter region of many target genes, such as Bad, Bax, Puma, Noxa and Bid 
to transactivate their gene expression. When enough Bad have been translated in the 
cytoplasm, it in turn associates with p53 to prevent the latter from entering nucleus. Bad 
expression is thus to be kept at a physiological level; moreover, dephosphorylated Bad 
is able to direct cytosolic p53 to mitochondria and promotes apoptosis via activating 
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Bak oligomerization and Cyt c release [140]. In summary, we found that cisplatin and 
paclitaxel induced Bad expression in wild type p53 expressing breast cancer cells 
whereas, Bad expression is only induced by cisplatin in mutant p53 expressing MDA-
MB-231 cells.  
In order to understand the role of Bcl-2 in cisplatin and paclitaxel induced 
apoptosis, MCF-7 and MDA-MB-231 cells were stably transfected with Bcl-2 plasmid. 
Results showed that cisplatin did not induce apoptosis in Bcl-2 over-expressing MDA-
MB-231 cells (Figure 4.24) whereas apoptosis was induced in MCF-7Bcl-2+ cells 
following cisplatin treatment (Figure 4.23). These results suggest that cisplatin activates 
a pro-apoptotic pathway that bypasses Bcl-2-mediated protection against apoptosis only 
in Bcl-2-overexpressing MCF-7 cells. This protection effect is accompanied with Cyt c 
release, MMP loss and activation of caspases [133]. Thus, previous reports noted 
cisplatin induced cell death type is controversial [141], our results clearly indicate that 
the mode of cell death triggered by cisplatin in MCF-7Bcl-2+ cells is mitochondrial 
apoptosis (Figure 4.23). 
In order to understand the cisplatin induced apoptosis mechanism in MCF-7Bcl-2+ 
cells, the modulation of Bcl-2 family members were investigated within 72 h. 
Activation of apoptosis by cisplatin in MCF-7Bcl-2+ cells occurred at a quite late time 
point compared to parental MCF-7 cells, which suggests a gradual engagement of the 
pro-apoptotic machinery to overcome Bcl-2-mediated anti-apoptotic potency (Figure 
4.23). Paclitaxel treatment for 72 h did not change total amount Bcl-xL expression level 
following, whereas cisplatin decreased the Bcl-xL expression at 72 h. Neither cisplatin 
nor paclitaxel had any effect on Bax expression (Figure 4.25). These results showed that 
cisplatin diminished Bcl-2 expression whereas paclitaxel did not exert any effect of Bcl-
2 expression. Together, these results suggests that cisplatin induces cell death by 
decreasing the expression of anti-apoptotic proteins Bcl-xL, while paclitaxel does not 
show any effect on the expression levels of these proteins. Therefore, paclitaxel is not 
effective in inducing apoptosis in cells with increased Bcl-2 anti- apoptotic proteins.   
To examine the cell and drug specific apoptotic induction in different kinds of 
breast cancer cells, we determined the pro-apoptotic Puma and Noxa mRNA levels in 
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MCF-7Bcl-2+ cells following cisplatin treatment (Figure 4.26-4.27). Results from paralel 
studies from our laboratory showed that both the cytoplasmic (transcription-
independent) pro-apoptotic role of p53 and its transcriptional activity in nucleus seem to 
be critical for cisplatin-induced apoptosis, particularly in cells with high anti-apoptotic 
potency due to overexpression of Bcl-2 [133]. Accordingly, the results from this study 
shown that Noxa, but not Puma, involved in the upstream of MMP loss in cisplatin-
induced apoptosis in MCF-7Bcl-2+ cells [133]. Induction of Noxa was shown to be p53-
dependent and strictly required for cisplatin-induced apoptosis in Bcl-2-overexpressing 
MCF-7 cells. In a complementary study, co-immunoprecipitation analysis showed that 
Noxa binds to Mcl-1 and displaces Bak to promote apoptosis. In contrast, Noxa did not 
interact with Bcl-xL or Bcl-2 in untreated or cisplatin-treated cells [133] suggesting that 
cisplatin induced Noxa expression leads to apoptosis independently from Bcl-2 
expression levels. 
Previous studies revealed the protective function of Bcl-2 against ROS production 
and lipid peroxidation [142-144], but the mechanism by which of Bcl-2 exerts these 
properties is not clearly understood. Here we showed that the gradual development of 
apoptosis is consistent with a gradual build-up of lipid peroxidation and ROS generation 
effects. Both ROS and lipid peroxidation have been reported to mediate cisplatin-
induced apoptosis in various cancer cell types [145]. Similar to these findings, acute 
apoptosis induced by cisplatin was shown to be mediated by ROS without the 
involvement of nuclear DNA-damage response [146]. Bcl-2 itself does not possess any 
antioxidant activity; rather, it may act indirectly to increase the levels and/or activities of 
endogenous antioxidants (e.g., glutathione or superoxide dismutase) within cells [147]. 
Moreover, Bcl-2 over-expression has effect on some antioxidant enzymes and GSH 
metabolism in different cell lines. In contrary, there are number of studies established 
that Bcl-2 has no effect on antioxidant enzyme levels and/or activities [142, 148]. 
Furthermore, mitochondria are a major source of ROS production and are involved in 
the regulation of Bcl-2 and apoptotic cell death induced by various stimuli. In agreement 
with an antioxidant role of Bcl-2, silencing or inhibition of Bcl-2 increased ROS 
generation in MCF-7 cells (Figure 4.28). Thus, pre-treatment of HA14-1 significantly 
enhanced cisplatin induced ROS generation and lipid peroxidation in MCF-7 cells. 
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Furthermore, cisplatin, paclitaxel and Bcl-2 inhibitor, HA14-1 increased the ROS levels 
in MCF-7 parental cells more than Bcl-2 overexpressing cells.  
Consistent with these findings, several reports showed that Bcl-2 overexpression 
protects cellular components such as lipids, proteins and DNA from oxidative stress. 
Therefore Bcl-2 eases lipid peroxidation induced by various oxidants such as H2O2 
[144]. Induction of ROS via various chemotherapeutics can lead lipid peroxidation. In 
order to investigate the effect of Bcl-2 in lipid peroxidation following cisplatin and 
paclitaxel treatment, MDA-TBA adducts derived from cell membranes were tested 
using TBARS assay. The high lipid peroxidation products were established following 
cisplatin treatment in Bcl-2 overexpressing MCF-7 cells for 72 h. In addition, inhibition 
or silencing of Bcl-2 induced lipid peroxidation in MCF-7 cells. In parallel studies, lipid 
peroxidation end products were shown to be involved in cisplatin-induced apoptosis 
downstream of Noxa-induction in MCF-7Bcl-2+ cells [133]. Furthermore, ROS 
generation was determined following drug treatment in MDA-MB-231 cells. Cisplatin 
increased ROS generation whereas paclitaxel was less potent to increase ROS. Pre-
treatment of MDA-MB-231 cells with HA14-1 increased drug-induced ROS generation 
in MDA-MB-231 cells. ROS generation upon drug treatment was found to be reversible 
by additional NAC treatment (Figure. 4.34). 
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Table 5.1 Summary of results of the study were presented following drug treatment in MCF-7 and MDA-MB-231 cells. 
  Bcl‐2 Ð Bcl‐2Ï 
  Bcl‐2 siRNA HA14‐1 Plasmid transfection 
MCF‐7 
Cisplatin  Apoptosis Ï 
ApoptosisÏÏ 
Pro‐apoptotic Bcl‐2 family members: 
PumaÏ 
Anti‐apoptotic Bcl‐2 family members: 
Bcl‐2, Bcl‐xL ÏÏ  
ROS generationÏÏ 
Lipid peroxidationÏÏ 
ApoptosisÏÏ 
Pro‐apoptotic Bcl‐2 family members:  
Bax≅, Puma and NoxaÏ 
Anti‐apoptotic Bcl‐2 family members:  
Bcl‐2 Ð 
ROS generationÏ 
Lipid peroxidationÏ 
Paclitaxel Apoptosis Ï 
Apoptosis Ï 
Pro‐apoptotic Bcl‐2 family members: 
Bax, Puma, Bad Ï 
Anti‐apoptotic Bcl‐2 family members: 
Bcl‐2, Bcl‐xLÐÐ 
Bcl‐2 mRNAÐÐ 
ROS generationÏ 
Lipid peroxidationÏÏ 
Apoptosis Ï  
Bcl‐2 protein level≅ 
Bax protein level≅ 
Bcl‐xL protein level≅ 
ROS generationÏ 
Lipid peroxidationÏ 
MDA‐MB‐231
Cisplatin  Apoptosis Ï 
ApoptosisÏ 
Pro‐apoptotic Bcl‐2 family members: 
Bax*, Puma, BadÏ 
Anti‐apoptotic Bcl‐2 family members: 
Bcl‐2, Bcl‐xLÐ 
ROS generationÏ 
Apoptosis≅ 
ROS generationÏ 
Paclitaxel Apoptosis Ï 
Apoptosis ≅* 
Pro‐apoptotic Bcl‐2 family members: 
Bax*, PumaÏ 
Anti‐apoptotic Bcl‐2 family 
members:Bcl‐2*Ð 
ROS generation≅ 
Apoptosis≅ 
ROS generationÏ 
* Not significant    
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6 CONCLUSION 
Since many agents have been identified or designed to target the Bcl-2 family at 
the mRNA or protein level, chemoresistance mechanism is intensively explored at the 
molecular level for each agent. Potential effects of Bcl-2 antagonists were similar but 
heterogeneous cell characteristics of tumors are determinative for their efficiency. The 
binding affinity anti-apoptotic Bcl-2 family inhibitors or transfection quality of gene 
therapy elements should be optimized to the clinically achievable concentrations. 
Agents with high specifity provide ready opportunities to be considered in drug-
resistance cases as broader acting agents may introduce unexpected responses to the 
chemotherapeutics and/or increase their systemic toxicities. Therefore, therapeutic 
potential of Bcl-2 targeting strategies should be further investigated at molecular level 
in various types of cancer cells. 
In this study, we confirmed that cisplatin and paclitaxel induced apoptosis in 
MCF-7 and MDA-MB-231 cells through the induction of MMP loss, caspase activation 
and modulation of Bcl-2 family members. According to our results, utilization of Bcl-2 
targeting strategies (siRNA or Bcl-2 inhibitors) has a therapeutic potential to increase 
the apoptotic efficiency of cisplatin and paclitaxel in both cell lines. However, the 
potentiating effect of Bcl-2 inhibitor (HA14-1) was found to be drug and cell type 
specific. In this study, as a first time we demonstrated that paclitaxel was less potential 
to induce apoptosis in HA14-1 pre-treated ER alpha negative MDA-MB-231 cells. Our 
results suggest that the efficiency of HA14-1 may not only depend on the inhibition of 
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Bcl-2 but also other pro-apoptotic and anti-apoptotic Bcl-2 family members. In that, 
alteration of other pro-apoptotic and anti-apoptotic Bcl-2 family members may dictate 
the apoptotic response when HA14-1 combined with chemotherapeutic drugs. Therefore 
further studies should investigate the how HA14-1 increase the drug induced apoptosis 
at molecular level in different cancer cell lines.  
We determined that cisplatin overcame Bcl-2 or Bcl-xL mediated resistance 
mechanisms in Bcl-2 overexpressing MCF-7 cells but not in Bcl-2 overexpressing 
MDA-MB-231 cells. Thus, p53 independent mechanisms which were activated by 
cisplatin in MDA-MB-231 cells could be successfully abrogated by Bcl-2. We conclude 
that this differential response in MCF-7 and MDA-MB-231 cells may be related to the 
selective activation of p53 pro-apoptotic pathway in Bcl-2 overexpressing MCF-7 cells. 
In addition, previous studies have suggested that cisplatin might induce cell death via 
mechanisms other than apoptosis but our results clearly indicate that the mode of cell 
death triggered by cisplatin in Bcl-2 overexpressing MCF-7 cells is mitochondrial 
apoptosis. 
The gradual development of apoptosis was shown to be consistent with a gradual 
built up of ROS generation which led to lipid peroxidation, suggesting that, Bcl-2 
antagonism or silencing approaches prevented the protection role of Bcl-2 against drug-
induced ROS generation and lipid peroxidation in breast cancer cells. Here, we 
confirmed that Bcl-2 possesses an anti-oxidant role and diminishes drug-induced ROS 
generation. Increased lipid peroxidation in Bcl-2 silenced MCF-7 cells may lead to 
targeting of lipid peroxidation end products to critical proteins and membranous 
structures and decreased Bcl-2 levels. However exact mechanism of this observation 
merits further investigation.  
In addition, our findings suggested that cisplatin induced lipid peroxidation was 
involved in apoptosis downstream induction of Noxa expression in Bcl-2 
overexpressing MCF-7 cells. However, further studies should be done to clarify how 
lipid peroxidation end products modulate Bcl-2 family members in cell death decision 
placed at mitochondria.  
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In summary, results of this study indicate two critical important findings. First, 
administration of Bcl-2 antagonists or silencing tools provided a detailed understanding 
of drug resistance mechanism in Bcl-2 overexpressing cancer cells. The utilization of 
Bcl-2 targeting strategies to augment the apoptotic response induced by cisplatin and 
paclitaxel has therapeutical potential. Here the most critical second observation that 
cisplatin treatment may overcome Bcl-2 mediated chemoresistance mechanism and this 
effect requires intact p53 pro-apoptotic pathway at both cytoplasmic/mitochondrial and 
nuclear. Lipid peroxidation end products are shown to be critical to understand how 
cisplatin overcome Bcl-2 mediated chemoresistance mechanism. 
These insights may be useful for the identification of new therapeutic target sites 
in Bcl-2 family proteins and elucidate alternative pathways to increase drug-induced 
apoptosis in drug-resistant cancer cells. 
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APPENDIX A 
CHEMICALS 
Name of material    Suppliers 
Acetic acid Sigma A9967 
Acrylamide/bis-acrylamide (30%) Sigma A6014 
Agarose low EEO Applichem A2114 
Ammonium persulphate (APS) Sigma A3678 
Anti β-actin antibody Cell signal technology 4967 
Apoptosis sampler kit Cell signal technology 9915 
Boric acid Applichem A0768 
Bromophenol blue Applichem A4968 
Bradford reagent Biorad 500-0001 
BSA Promega W3841 
Caspase inhibitors BD Biosciences 
Carbondioxide Karbogaz 
Chloroform Merck 102431 
Cisplatin  Bristol Myers Squibb 
CM-H2DCF-DA Molecular Probes C6827 
CompleteTM protease inhibitor cocktail 
tablet 
Roche S29130 
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Coomassie brilliant blue Merck 1.02082.0005 
Developer solution Agfa 
Dimethlysulphoxide (DMSO) Sigma D2650 
Dithiothreitol (DTT) Sigma D9779 
DNA gene ruler 1kb Fermentas SM1353 
DNA loading dye 6X Fermentas SM1353 
Etilendiaminetetraaceticacid (EDTA) Riedel-de-Haen 32221 
Ethanol absolute Riedel-de-Haen 
Ethanol technical grade Riedel-de-Haen  
Ethidium bromide Merck OCO28942 
Foetal bovine serum (FBS) 
Biological industries 
PAN 
Fixer solution Agfa, USA 
Fugene HD Roche 1107.04962095001 
Glycerol  Riedel-de-Haen 15523 
Glycine Amresco 0167 
Hydrochloric acid (HCl) Merck 100314 
HA14-1 Calbiochem 
HEPES Sigma S7006 
IGEPAL CA-630 (NP-40) Sigma I3021 
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Isoprapanol (2-propanol) Riedel-de-Haen 24137 
Potassium chloride (KCl) Fluka 60129 
Potassium hydroxide (KOH) Riedel-de-Haen 06005 
Laemmli 2X Sample buffer Sigma S3401 
Liquid nitrogen Karbogaz 
2-Mercapthoethanol Sigma M370-1 
Methanol Riedel-de-Haen 24229 
Magnesiumchloride (MgCl2.6H2O) Sigma M9272 
Sodium chloride (NaCl) Riedel-de-Haen 13423 
Sodiumbicarbonate (NaHCO3) Riedel-de-Haen 32320 
Sodium hydroxide (NaOH) Merck 106462 
Non-fat dry milk Sütaş 
Paclitaxel Bristol-Myers Squibb 
Phosphate buffer saline 10X (PBS) PAN chemical 
Phosphate buffer saline 1X (PBS) Biological industries 
Penicillin/Streptomycin Biological Industries 
Phenylmethylsulphonyl fluoride (PMSF) Sigma P7626 
Plastic wrap Cook 
Pro-Apoptosis Bcl-2 family antibody 
sampler kit 
Cell signal technology 9942 
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Pro-survival Bcl-2 family antibody 
sampler kit 
Cell signal technology 9941 
Rhodamine 123 Molecular Probes R302 
RPMI 1640 Biological Industries 
RNA loading dye 2X Fermentas R0641 
Sodium dodecyl sulphate (SDS) Sigma L4390 
N,N,N',N'-Tetramethylethylenediamine 
(TEMED) 
Sigma T7029 
N-acetyl cystein Sigma A7250 
Tris base Fluka 93349 
Trizol Gibco 15596-026 
Trypsin-EDTA (1X) Biological Industries 
Tween-20 Merck 822184 
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APPENDIX B 
MOLECULAR BIOLOGY KITS 
MTT cell proliferation kit (Roche) 
M30 ELISA assay (Peviva AB) 
siRNA transfection kit (Qiagen) 
One-step RT-PCR kit (Qiagen) 
RT reaction kit (Qiagen) 
SYBR green assay kit (Qiagen) 
ECL western blotting kit (GE Biosciences) 
ECL Advance western blotting kit (GE Biosciences) 
Qiagen plasmid Midi kit (Qiagen) 
Qiagen plasmid Maxi kit (Qiagen) 
Caspase activity apoptosis sampler kit (Invitrogen) 
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APPENDIX C 
OTHER MATERIALS 
Name of material Supplier 
Hybond P membrane (PVDF) Amersham Biosciences RPN2020F 
Kodak OMATXR film Kodak 
Mass ruler DNA ladder mix Fermentas SM0403 
Protein MW marker Fermentas SM0441 
Amersham RPN303F 
RNase A Roche1119915 
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APPENDIX D 
EQUIPMENT 
Autoclave:   Hiclave HV-110, Hirayama 
   Masa üstü otoklav, Nüve 
Balance:  Sartorious BP211D 
   Sartorious BP221S 
   Sartorious BP610 
Blot module:  Biorad Mini Protean 
Centrifuge:  Eppendorf, 5415C 
   Eppendorf 5415D 
   Eppendorf 5415R 
   Heraus multifuge 3L 
   Hitachi sorvall RC5C Plus 
CO2 incubator: Binder 
Deepfreeze:  -70 oC Heraus Hfu486 Basic 
   -20oC Bosch 
Distilled water: Milipore, Elix S 
   Millipore MilliQ Academic 
Electrophoresis: Labnet Gel System 
   Biorad Mini Protean 
Gel Documentation: Gel Doc Biorad 
Ice Machine:  Scotsman AF20 
Incubator:  Memmert model 300 
   Memmert model 600 
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Laminar flow:  Heraus Hera Safe HS12 
Magnetic stirrer: VELP Scientifica ARE heating magnetic stirrer 
   VELP Scientifica microstirrer 
Microliter pipette: Gilson Pipetman 
   Finnpipette digital 
   Eppendorf pipette 
Microwave oven: Bosch 
pH meter:   WTW, pH 540 GLP Multical 
Power supply:  Biorad Power pac 300 
Refrigerator:  + 4oC Bosch 
Shaker:  Forma Scientific Orbital Shaker 4520 
   New Brunswick orbital shaker Innova 4330 
   New Brunswick orbital shaker C25HC 
Sonicator:  Vibracell 75043, Bioblock 
Spectrophotometer: Schimadzu UV-1208 
   Nanodrop 
   Amersham 2000 spectrophotometer 
   Schimadzu UV-3150 
Speed vacuum: Savant Speed Vac Plus Sc100A 
   Savant refrigerated vapor trap RVT 400 
Thermocycler: Eppendorf Mastercycler gradient 
   Biorad My Cycler IQ5 quantitative PCR 
Vacuum:  Heto, Master Jet Sue 300 Q 
Water bath:  Huber, Polystat ccl 
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